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Abstract 
 Canine tracheal collapse is a condition results in the weakening of tracheal cartilage rings. As the 
cartilage weakens, the trachea collapses, causing difficulty breathing, discomfort, and other medical 
issues. Self-expanding nitinol stents are utilized to restore and sustain the trachea’s internal area. These 
stents fail to effectively resist migration, resulting in the stent dislocating and irritating the surrounding 
tracheal tissue. Following validation testing of three polymers, chitosan, polycaprolactone (PCL), 
and poly-L-lactic acid (PLLA), it was determined that the chitosan polymer coating best fulfilled the design 
objectives, due to its ability to produce dip coating, low mechanical integrity impact, 
low cytotoxicity, mucoadhesive properties, and low production cost.  
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1.0 Introduction 
Yorkshire Terriers are the ninth most popular registered dog breed in the United States 
according to the American Kennel Club’s 2016 rankings [1].  A disease known as tracheal collapse 
is most commonly found in small breed dogs, with the highest prevalence in Yorkshire Terriers 
[2], [3]. A healthy trachea is a tube that runs from the larynx to the bronchi composed primarily of 
C-shaped cartilage rings and connective tissue [4], [5]. Functionally the trachea allows inhaled air 
to pass through, while filtering, warming, and adding moisture to it to make it favorable for the 
lungs [6]. Tracheal collapse weakens the structure of tracheal cartilage, leading to the inward 
collapse of the cartilage rings [2], [3]. Depending on the severity of the collapse, the effects can 
range from irritation and “goose-honking” coughs to fainting, difficulty breathing, or death [3], 
[5]. Tracheal collapse progression in Yorkshire Terriers is exacerbated by genetic and 
environmental factors, and requires treatment to minimize the discomfort and suffering of the dog 
[2], [3]. The condition is largely manageable in the early stages without the need for surgery. 
Tracheal collapse is always managed non-invasively prior to surgical options. Medical 
management options include weight loss regimens, cough suppressants, and sedatives to limit the 
dog’s excitement [3]. While implementing exercise and dietary regulations requires additional care 
and supervision, medical options can be costly dependent on the drug used. Management may not 
permanently offset the propagation of severe trachea collapse, requiring further corrective action 
if it does progress to a severe case. When management fails to be effective, surgical intervention 
is utilized. Two implantable device types exist regarding tracheal collapse, extraluminal prosthesis 
and intraluminal stenting [2], [5]. Extraluminal prosthesis utilizes ring-like strips of plastic applied 
to the surface of the trachea externally pull it back into shape. Intraluminal stents are mesh, tube 
shaped devices used to expand the opening of a trachea, forcing the airway back into its original 
shape. The gold standard for this type of treatment is the Vet Stent Trachea designed by Infiniti 
medical. The Vet Stent utilizes nitinol as a material to self-expand from the catheter sheath to full 
size. Approximately one quarter of implanted tracheal stents will fracture, while one third will 
develop unwanted granulation tissue in the stent due to the inflammatory response of the 
surrounding tissue [2]. A need exists at Tufts Veterinary’s Foster Hospital for Small Animals for 
a device that is capable of outlasting current options and improving the overall quality of life of 
the recipient.  
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The client, Dr. Elizabeth Rozanski at the Foster Hospital for Small Animals and Tufts 
Cummings School of Veterinary Medicine, seeks an improved treatment method over existing 
stents to improve the quality and longevity of treating tracheal collapse in small breed dogs, 
specifically Yorkshire terriers. The prevalence of tracheal collapse in a widely popular dog breed 
results in the need for effective, affordable treatment option for the disease. The goal of this project 
lies in developing and testing modifications for use with existing canine tracheal stents. A 
successful modification will decrease granulation tissue growth around the stent, while keeping 
the stent in place following implantation. Some additional design requirements include minimizing 
airway irritation, preventing cell death due to toxic materials, encouraging the growth of beneficial 
epithelial cells to coat the stent, and extending the lifespan of the device to match that of the 
recipient, approximately seven or eight years. The modification must also interface with currently 
marketed stents and be produced at a competitive price; the Infiniti Vet Stent utilized by Tufts 
veterinarians costs approximately $1,100, however the hospital will pay a maximum of 
approximately $1,500 for a stent capable of lasting longer and outperforming the current options 
[3]. With this in mind, the modification may cost up to a maximum of $400 to manufacture. 
To accomplish this goal, several components must be applied to this project. Modification 
options must be considered and tested for both mechanical integrity and biocompatibility. The 
stent modification must be capable of withstanding the forces that the stent itself undergoes. They 
must also be tested to determine if the coatings are able to enhance the cellular adhesion of the 
stent to reduce the risk of dislodging. The modification is to be tested in a cellular environment to 
ensure that they were not cytotoxic and would not cause tissue abrasion or an inflammatory 
response. If successful, the modification will allow for cell adhesion, prevent cell death, and prove 
viable as an option for Tufts Veterinary Hospital to improve existing stents on the market. The 
overall success of this project may allow improvements in not only canine veterinary medicine, 
but also may be applied to other veterinary fields, such as feline and equine medicine [5]. Such a 
modification can additionally be applied to any stent that is developed similarly to a canine tracheal 
stent, allowing for universal application as needed by clinics. 
  
 3 
 
2.0 Literature Review 
2.1 The Trachea and Tracheal Collapse 
2.1.1 Tracheal Anatomy and Physiology 
 The trachea is a tube-shaped structure that extends from the larynx to the bronchi located 
anteriorly to the esophagus, along the neck of the dog. It is composed of anywhere between 35 and 
45 C-shaped hyaline cartilage rings connected by annular ligaments [4], [5]. The width of the 
cartilage rings is roughly 4mm, and the annular ligaments are roughly 1mm in width [4]. The 
diameter of the structure falls in the range of 9mm to 17mm, dependent on the size of the dog [3]. 
Mechanically, the cartilage rings serve as a solid, non-collapsible structure, while the annular 
ligaments that connect the cartilages allow the trachea to flex and bend [4]. The trachea splits at 
the end closest to the bronchi to allow it to connect to both lungs [5]. The dorsal (upper) component 
of this structure, unlike the c-shaped cartilages, is composed of mucosa, connective tissue, and 
tracheal muscle, and serves as the point where the C-shaped cartilages connect and form a complete 
tubular structure[5]. The lining of the trachea is composed of “pseudostratified, ciliated epithelial 
mucosa” [7]. 
 The trachea is known as the “windpipe” and serves as a crucial component of the 
respiratory tract. The primary function of the trachea is to conduct air from the pharynx and larynx 
to the bronchi, which allows air to reach the lungs. The cilia that line the surface of the trachea, 
along with mucus that is produced by mucous membranes, are utilized to trap and remove irritants 
from the windpipe [7]. Additionally, the trachea is involved in warming, cleaning, and humidifying 
the inspired air. These actions keep the lungs from desiccating, and help ensure they function under 
optimal conditions at all times [7], [8]. A healthy trachea resists changes in applied pressure during 
inhalation and exhalation, allowing it to maintain its shape and prevent the loss of tracheal lumen, 
the opening of the trachea itself [7]. 
2.1.2 Tracheal Collapse 
 Tracheal collapse is a disease that results in a loss of tracheal lumen due to the mechanical 
failure of the tracheal structure. There are two ways in which this disease may propagate based on 
the axis upon which the collapse occurs. Lateral collapse, where the side walls of the C-cartilages 
collapse medially, is the less common of the two, and is often developed following surgical 
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intervention for dorsoventral collapse [9]. Dorsoventral collapse, the most common classification 
of tracheal collapse, occurs when the dorsal membrane loosens and collapses into the tracheal 
space [9].  
The exact cause of the disease is unknown, but it is suggested to be influenced by genetics 
due to the tendency for toy and miniature breed dogs, particularly Yorkshire Terriers, to experience 
it [2], [9]. Additionally, the disease may be exacerbated by environmental and lifestyle factors 
including high air temperatures, living with smokers, forces applied by collars, obesity, and 
excitement [2], [5]. The cartilage rings of the trachea are found to reduce in rigidity and deform 
due to reduced contents of glycosaminoglycan, glycoprotein, chondroitin sulfate, and water in the 
hyaline cartilage [2]. This reduced rigidity furthers the propagation of the collapse, and further 
inhibits respiratory ability. Tracheal collapse is graded on a four-level scale based on lumen 
diameter reduction: Grade I for up to 25%, Grade II for up to 50%, Grade III for up to 75%, and 
Grade IV for up to 100% loss [5] . The level of collapse is best observed by utilizing endoscopy, 
as it allows for a dynamic view of both inspiratory and expiratory action [5]. This allows for the 
full breathing cycle to be examined, as the trachea may change in shape during respiration due to 
weakened tracheal structures, presenting less collapse during certain phases than others. Tracheal 
collapse causes respiratory issues including coughing in normal cases, and difficulty breathing and 
sudden collapsing in severe cases [2], [7]. Additionally, the increased airway irritation that occurs 
with the disease leads to mucous membrane inflammation, which in turn inhibits mucous 
production, leading to further issues with irritants [9]. 
2.2 Treatment Options 
2.2.1 Management 
Medical management is utilized prior to any surgical methods to attempt to delay the 
progression of the collapse. Non-medical management options include utilizing harnesses instead 
of collars, limiting exposure to irritants, and implementing dietary weight-loss regimens to reduce 
the pressure and irritation applied to the trachea [5]. The types of medications utilized include 
antitussives, bronchodilators, and steroids [2], [5]. Antitussives are utilized to reduce the dog’s 
cough and provide relief from the irritation coughing causes the trachea [2]. Bronchodilators 
reduce the trachea’s resistance to airflow by reducing intrathoracic pressure, improve the cilia’s 
ability to clear particles and mucous from the airway, and allow for the diameter of the trachea to 
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increase [2]. Steroid therapy has been shown to reduce airway irritation, and in a recent study of 
stanozolol, shown to increase the levels of chondroitin sulfate in the tracheal cartilage [2]. While 
these drugs relieve the symptoms of tracheal collapse and work to successfully manage early and 
less severe cases, more severe late-stage cases require further surgical intervention [2], [5]. 
2.2.2 Tracheal Rings 
 Tracheal rings, also known as extraluminal prostheses, are C-shaped rings that are typically 
made of plastic and attached to the external surface of the trachea using stitches [2], [5]. These 
rings are able to increase the tracheal lumen and prevent pressure-based collapse, offering a longer-
term solution to collapse [5]. While positive outcomes are reported in anywhere from 75 to 89% 
of dogs after the placement of extraluminal prostheses, including a median survival time of 4 years 
and 6 months, this type of treatment entails additional risks [2]. The surgery is complicated, and 
requires the surgeon to cut open the surrounding structures to reach the tracheal surface, which can 
lead to additional non-tracheal complications [2], [5]. Laryngeal paralysis, a major complication, 
can occur in 11 to 30% of extraluminal prostheses recipients, which may require additional surgery 
to correct [2], [5]. As a result of the difficulty and risks of this surgery, intraluminal tracheal stents 
are the most commonly used device [2], [5]. 
2.2.3 Stents 
 When surgical intervention is required to treat a Yorkshire Terrier’s tracheal collapse, the 
most commonly utilized method is intraluminal stent implantation. The stent is implanted by 
sliding it down the dog’s throat typically using either a sheath catheter or a balloon catheter. The 
balloon catheter operates by sliding the stent into place and then inflating the balloon to expand 
the stent to full size. Once the stent is completely in place, the balloon is deflated, the catheter is 
removed, and the surgery is complete [10]. The sheath catheter is utilized in the delivery of shape 
memory alloy stents, most commonly Nickel-Titanium (nitinol). These materials can be freely 
bent and stretch while they are at low temperatures but return to a predetermined form when a 
stimulus is applied. In the case of stents, the stimulus is reaching a temperature known as the 
transformation temperature. Using the sheath catheter method, the stent is inserted into the trachea 
similar to the balloon catheter method, but without the need to manually expand the stent. The 
stent’s predetermined form is a cylinder with a slightly larger diameter than the trachea, and it 
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returns to this form upon reaching body temperature. The catheter is then removed, and the stent 
is left deployed.  
 The nitinol tracheal stent is the primary stent in use by vets for treating tracheal collapse. 
This is due to the material’s superior fatigue strength, which is necessary for withstanding the 
typical bending movements of a dog’s neck. The high fatigue strength of nitinol is due to its shape 
memory properties. Being a shape memory alloy, nitinol also has a property known as super 
elasticity. Essentially, when nitinol is at a temperature slightly higher than its transformation 
temperature, it is capable of continually recovering from strains for an extended period of time. 
For a stress of about 30 kPa, this can be up to and over 10,000,000 cycles [11]. This is due to 
multiphasic nature of nitinol which causes the shape memory. At low temperatures, nitinol is in a 
phase known as martensite, and it can be freely bent and flexed. Once it passes the threshold of its 
transformation temperature, it enters the austenite phase, which causes it to return to a 
predetermined form. While the nitinol is in the austenite phase, any stresses applied can force it 
back into the martensite phase. If the temperature remains above the transformation temperature, 
the nitinol will return to the austenite phase and its chosen form upon the release of the applied 
stress. 
 The most recent advances in stents have occurred with drug eluting stents and 
biodegradable stents. Biodegradable stents are generally made of a polymer that is designed to 
degrade over time until it is completely removed from the body. In the case of canine tracheal 
stents, biodegradable stents are not feasible. This is due to the fact that the stent would need to 
remain in the dogs trachea for up to 15 years. 
Drug eluting stents are coated in a polymer that is loaded with a drug, allowing for the drug 
to be released into the body as the polymer degrades. For a canine tracheal stent, the eluted drugs 
are used to control the body’s negative foreign body reaction. Drugs commonly utilized in these 
stents include Dexamethasone, Biolimus A9, Sirolimus, Paclitaxel, and Everolimus. Excluding 
Paclitaxel, these drugs are immunosuppressants [12]. Paclitaxel is a antiproliferative utilized 
specifically for preventing the growth of scar tissue. The stent’s polymer coating is loaded with 
one of these drugs, and the body’s natural processes slowly break down the polymer over time. As 
the polymer breaks down, the drug that the coating was loaded with is slowly released. Before a 
drug eluting stent is released to market, its polymer degradation and drug release profiles are 
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studied in detail, to ensure that the rate that the body is exposed to the drug is well-known and 
controlled. 
2.2.4 Current Limitations of Stents 
 The major limitations of stents are based around biocompatibility. Specifically, the foreign 
body response caused by the immune system serves as the greatest limitation. After implantation, 
the most common cause of failure in tracheal stents is the growth of scar tissue, or fibrosis. Once 
the stent is implanted, physiological reactions, such as inflammation, occur. This inflammation 
further triggers a cascade of other immune responses as the stent agitates the surrounding tissue 
[13]. The immune system essentially tries to attack the foreign body, the stent in this case, or at 
least isolate it from the rest of the body to prevent any potential damage. Fibrosis, the production 
of a fibrotic tissue in response to a wound, is the method in which the immune system isolates the 
stent from the tracheal wall. This is due to the body perceiving the interaction between the tracheal 
wall and stent as a type of wound [14]. This fibrotic tissue is more dense than regular tissue, and 
can also damage the structure of underlying tissue [15]. As this fibrotic tissue grows, it pushes on 
the stent, applying elevating levels of pressure as more tissue is grown, eventually breaking the 
stent. The previously mentioned drug eluting stents are thought to be quite useful in decreasing 
fibrotic tissue growth. The drugs released from drug eluting stents tend to be either 
immunosuppressants, which slow or stop immune response, or antiproliferatives, which prevent 
the growth of certain tissues [16]. 
2.3 Biocompatibility 
2.3.1 Cytotoxicity 
 Cytotoxicity is the property of a material that leaches toxic chemicals that are harmful to 
cells. If a cell is exposed to enough of a cytotoxic material it will trigger cell death or apoptosis. 
Implanting a cytotoxic material into a living organism can cause an area of necrosis, or tissue 
death, to develop around the implant [17]. Due to this it is important to consider possible cytotoxic 
effects when designing a device that will be implanted into an organism especially if the device is 
meant to remain in the body for long periods of time. It is possible that materials that are not 
inherently cytotoxic may still break down into cytotoxic byproducts throughout the life of an 
implanted device such as hip implants which can use ultra-high weight polyethylene (UHMWPE). 
UHMWPE is not toxic in small amounts but when a fibrotic layer of tissue grows over the implant 
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and isolates it from the body, the UHMWPE can build up cause cell death [18]. and However, 
research prior to testing ensures that this rarely occurs. 
2.3.2 Granulation Tissue Growth 
 The development of granulation tissue is a normal bodily immune response to a wound. 
When a wound occurs, it is important for the body to quickly seal it to prevent excessive blood 
loss. Due to the need for the body to close wounds quickly, normal healthy tissue does not have 
time to grow as the would clots. Instead fibroblasts quickly produce fibrin, which triggers the 
formation of a network of fibrin at the wound site. This signals the immune system to remove the 
damaged tissue through phagocytosis as new healthy tissue begins to grow. To complete the 
healing of the wound, the new healthy tissue is vascularized in order to reconnect it to the 
circulatory system and allow for normal cell life to continue [19]. 
Despite the growth of granulation tissue being a normal healthy response to a wound, it 
can also be detrimental for blood vessels, the trachea, and other open ducts if the tissue continues 
to build up until it completely occludes or blocks the duct. All implants trigger some form of 
foreign body response, which is the body’s way of protecting itself from foreign contaminants. In 
order to create a healthy implant, the foreign body response needs to be minimized to prevent the 
excessive buildup of granulation tissue [19]. 
2.3.3 Epithelialization 
 While fibrosis is tissue growth that is detrimental to implanted stents, small amounts of 
tissue growth on and around stents is not always bad. Epithelial tissue growth is vital to preventing 
stent migration and thereby increasing the longevity of an implanted stent. Epithelization is the 
process of growth of epithelial tissue over the stent in a layer of cells about 4-5 cells deep.  
 For stents, epithelization is vital to biocompatibility. One of the main problems that is 
addressed by increasing the stents biocompatibility is the growth of scar tissue. In growing this 
scar tissue, the body is attempting to isolate and attack the stent as a response to stent migration 
which causes irritation and inflammation. When a layer of epithelial tissue grows over the stent, it 
isolates the stent since the body is not equipped to break down a stent itself. Essentially, the 
epithelial tissue separates and protects the stent from the body, preventing the immune system 
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from detecting the stent, and in turn preventing the fibrotic response to it [20]. Without the fibrotic 
tissue growth damaging the stent, its lifespan can be greatly enhanced.  
 Any movement of the stent can cause injury to the trachea, which can provoke an immune 
response. Epithelization is able to prevent migration of the stent, thereby reducing the chances of 
this potential issue[21]. As long as the stent is designed to allow for epithelial exposure, it will be 
covered on all sides by cells. This epithelial layer that is grown over the stent immobilizes it, 
preventing any movement that could potentially cause damage and reducing the chances of the 
stent being coughed up. 
2.4 Coatings 
2.4.1 PLLA 
 PLLA, or poly-L-lactic acid, is biodegradable polyester. It is a well-known polymer for use 
in stent coatings, being one of the more commonly used coatings [22]. PLLA is used in both 
copolymer and block copolymer form with other polymers. PLLA degrades primarily by 
hydrolysis and is not known to produce any toxic byproducts as it degrades. Its monomer, lactic 
acid, is a natural product of the human body, and is subsequently turned into water and carbon 
dioxide by the body’s natural metabolic processes [23]. One of its downsides is that it degrades by 
bulk degradation, and not by surface degradation. Bulk degradation is degradation that occurs to 
the entire volume of the polymer at once. The chemical reactions that start at the exterior of the 
polymer cause chain reactions that weaken the interior of the polymer volume as well. Surface 
degradation, however, is when only the outmost portion of the polymer degrades. Once that portion 
has completely degraded, the new outermost portion degrades. Bulk degradation is often thought 
of as inferior to surface degradation, as bulk degradation will cause the subject polymer to lose 
physical integrity much sooner. 
 The other forms of PLLA, PDLA, and the primary form, PLA, can all be used in coatings 
as well. The primary difference between these forms is the physical orientation of the molecules 
that make them up. PLA is the common form, with PLLA and PDLA being the variations from 
the common form. Their mechanical properties vary widely, and they have different degradation 
rates. PLLA, the strongest of the three, degrades within a period of anywhere between 12 months 
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to more than 24 months. PDLA, with a lower modulus than PLLA, degrades in 12 to 16 months 
[24]. Standard PLA completely degrades within 12 months [25]. 
2.4.2 PGA 
 PGA, or poly glycolic acid, is a biodegradable polymer. PGA was not originally considered 
to be a useful material for implantation due to its short lifespan in the body, about 90 days. Because 
it hydrolyzes quickly it did not seem suitable for any load-bearing applications because it would 
dissolve before the body could heal properly. However, it is currently used in dissolvable sutures, 
which don’t need to remain in the body as long as other implanted devices, such as hip implants 
or stents [26]. 
2.4.3 PLGA 
 PLGA, or poly lactic co-glycolic acid, is a copolymer made up of glycolic acid and lactic 
acid. It has already been FDA (Food and Drug Administration) approved for a variety of uses 
within the body due to its biocompatible and biodegradable qualities. PLGA degrades by 
hydrolysis of its ester bonds. When hydrolysis occurs PLGA breaks down into its polymer 
components: glycolic and lactic acid. Both glycolic and lactic acid occurs naturally within and is 
used by the body, which makes PLGA have a minimal foreign body response. By changing the 
ratio of lactic acid to glycolic acid, the properties of PLGA, such as degradation rate, can be 
tailored to various applications, including implants and sutures [27]. 
2.4.4 PCL 
 PCL, or polycaprolactone, is a biodegradable ester that degrades by hydrolysis breaking 
down the ester bonds. It also has a low melting point for polymers, 60C, which allows it to be 
easily formed by submerging it in water heated to temps near this for a short period of time. PCL 
also degrades slowly compared to other polymers, which makes it a good candidate for long-term 
implantation. Unfortunately, it is also resistant to adhesion, which is problematic when trying to 
keep an implant in place without the aid of other adhesives or sutures. 
2.4.5 PEG and PEO 
 Polymers such as PEG (polyethylene glycol) and PEO (polyethylene oxide) can be used to 
coat other materials to increase their biocompatibility. PEG and PEO are the same polymer with 
different molecular weights, meaning they all have the same monomer subunit, but each of these 
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polymers has a different number of monomers attached in a chain to form one polymer [28]. PEG 
has been used to coat drugs to carry a hydrophobic drug in a micelle, or self-forming vesicle, of 
hydrophilic PEG polymers in a process called PEGylation [29]. 
2.4.6 Chitosan 
 Chitosan is a biological polymer that is derived from chitin, the primary component of crab 
shells. It is used in a wide variety of industries, from agriculture to medicine, due to its antifungal 
and antibacterial properties. A major issue of chitosan is its solvability. Traditional solvents, such 
as acetone, chloroform, and water, are ineffective on chitosan. Generally, a weak acid, such as 
acetic acid, is required to dissolve it.  
 Another interesting property of chitosan would be its mucoadhesion, which allows it to 
easily adhere to mucosal membranes. This mucoadhesion allows chitosan to be effectively used as 
a drug delivery method or as an implant material in environments rich with mucus. Chitosan also 
dissolves in acidic environments, making it an effective drug delivery method in unique 
environments [30]. 
2.5 Drugs 
2.5.1 Sirolimus 
 Sirolimus is a drug used in drug eluting stents. It functions as an immunosuppressant and 
an antiproliferative, preventing tissue growth caused by immune reactions. Tissue growth caused 
by an immune reaction is the result of an extended chain of molecular reactions that occur in the 
body. Sirolimus achieves its immunosuppressant properties by inhibiting one of the early steps in 
this chain reaction, the activation of immune T and B cells, by targeting the protein kinase 
mammalian target of rapamycin (mTOR). mTOR is a central part of two protein complexes, 
mTORC1 and mTORC2, that directly affect cell growth and movement. Without this activation 
occurring, the amplification of the immune response is greatly diminished, which in turn slows or 
prevents the growth of fibrotic tissue produced by the immune system [31]. 
 Sirolimus can be potentially dangerous, due to it being able to weaken the patient’s immune 
system. When this occurs, a simple infection can potentially become deadly. In conjunction with 
this, Sirolimus is also an antiproliferative, which can slow the healing of other wounds [32]. 
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2.5.2 Everolimus 
 Everolimus is a derivative of Sirolimus, and as such works similarly. It acts as an 
immunosuppressant, slowing or stopping the immune response to an implant. It has only a very 
subtle chemical difference from Sirolimus, the exchange of a hydrogen atom for a 2-hydroxyethyl 
chain. The primary change that this causes in the drug is that it is much more soluble, and thus 
bioavailable, than Sirolimus [33].  
 The changes in Everolimus that make it different from Sirolimus also seem to decrease the 
overall immune suppression, reducing the risk of infections becoming deadly. This may be because 
the drug works on only the mTORC1, rather than both the mTORC1 and mTORC2 like 
Sirolimus.[34]. 
2.5.3 Paclitaxel 
 Paclitaxel is an antiproliferative drug that works by stabilizing the microtubules found 
within cells. Essentially, this causes the cells to be unable to progress through mitosis. After being 
stagnated at this point, the cells will either be forced to go through apoptosis or revert to the G 
phase. For tracheal stents, this prevents the cell proliferation that is caused in response to an 
implant [35].  
 Paclitaxel operates in a relatively unique way. Most drugs that operate on microtubules 
disassemble them, but Paclitaxel prevents them from disassembling. Paclitaxel has extremely poor 
solubility and tends to have a large variety of side effects ranging from nausea and tingling in the 
limbs to fever and female infertility. As such, doctors tend to prescribe additional drugs to manage 
the side effects of Paclitaxel [36]. 
2.6 Processing 
2.6.1 Polyelectrolyte Multilayers 
 With more recent advances in stent design, controlled drug release has become a beneficial 
property for controlling the host’s immune response. As such, a method for tunable release 
profiling of stents known as polyelectrolyte multilayering is utilized to not only allow for the 
controlled elution of drugs carried by stents, but also to enhance the existing surface properties of 
implanted devices. This method also enables the deposition of coatings on almost any possible 
substrate, including stents and other devices [37], [38]. 
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 Polyelectrolyte multilayers (PEMs) are utilized to allow a device to release drugs for a 
controlled duration following implantation. In doing so, the foreign body immune response can be 
suppressed, or healing can be accelerated. To create a coating allowing for tunable drug release, 
the layer-by-layer deposition method of polyelectrolytes, where polyanion (negative) and 
polycation (positive) polymers are layered onto the device, is utilized [37], [38]. These layered 
polymers are sensitive to pH changes within the environment they are subjected to, and will 
degrade in a profile that can be measured in vitro [38]. Common drug release methods that take 
advantage of this pH sensitivity include pH-induced swelling, pH-induced degradation of 
hydrogen-bonded films, and salt-induced degradation [37]. 
 Additionally, PEMs grant biocompatibility properties to implant surfaces. Since the PEM 
coating takes on the properties of the polymers utilized to develop it, antibacterial and 
antimicrobial properties are feasible to obtain [37], [38]. For example, chitosan, a common 
biocompatible coating material, can be utilized in conjunction with other polymers, such as 
hyaluronic acid, to bestow properties ranging from bacteria resistance and implant anchoring to 
cell adhesion [38], [39]. A range of compatible polymer bilayers can grant properties beyond the 
standard biocompatibility increases found in typical coatings. 
 Applying such coatings requires two primary phases. The polymers must be dissolved in 
appropriate solvents to become liquid or gelatin-like substances. Following coating preparation, 
the coating is applied to the device, in the case of stent wires it can applied either by spraying the 
surface with the coatings or through dip coating. This allows for simple coatings to be applied even 
in cases where access to expensive processing equipment is limited.  
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3.0 Project Strategy 
3.1 Initial Client Statement 
 The initial client statement covered a wide array of issues presented by canine tracheal 
collapse and included components that were eventually removed: “The goal of this project is to 
research and test materials and coatings for canine tracheal stents. A successful stent will not break 
due to forces applied by the dog (breathing, coughing, moving, flexibility), decrease scar tissue 
growth around the stent, and keep the stent in place following implantation. Further, to develop an 
implantation method for tracheal stents that conform to a dog’s tracheal anatomy, and a testing 
method for said stent and implantation device.” The client's need for improved canine trachea 
stents and the problems associated with existing stents served as the basis for this project. Dr. 
Rozanski presented an ideal price range for a newly developed stent ($1,500 or less in cost to the 
hospital) and encouraged the team to improve upon existing stents. Most stents utilize either a 
balloon or sheath catheter, so utilizing either existing deployment method allowed for ease of use. 
3.2 Design Requirements (Technical) 
 Upon receiving the initial client statement, a collection of various objectives was compiled. 
Based on a hierarchy of importance, these objectives were divided into primary and secondary, 
and would become the overall end goals the project would work toward. Using these objectives as 
a base, the primary functions of the design were determined. Finally, using further information 
gleaned from the sponsor and the literature review, the major constraints of the project were also 
defined.  
The primary objectives were determined to be the overall durability of the device, the 
ability of the device to maintain the opening of the trachea, and the biocompatibility of the device. 
The secondary objectives, the lower priority goals that would enhance the device, were determined 
to be the compatibility of the device with current delivery methods, the low level of invasiveness 
of the device’s implantation, and the cost of the device. These primary and secondary objectives 
determine the necessary enhancements to be made on the current technology. To enhance existing 
canine tracheal stent technology and allow for future devices to utilize the innovations made by 
this project, an applied coating was determined to be the best option. 
 15 
 
3.2.1 Primary Objectives 
 The primary objectives of this project center on increasing the quality and length of life for 
the dogs that require a device to correct tracheal collapse. With respect to this need, ensuring that 
the device possesses the ability to successfully maintain the lumen of the reopened trachea serves 
as a key objective. The cross-sectional area of the trachea should be maintained as close to 100% 
of the original size as possible to allow for normalized respiratory action.  
Typically, Yorkshire Terriers are diagnosed with high grade tracheal collapse, which 
requires surgical intervention and/or a device for correction, at approximately 7 years of age. As 
the average reported lifespan of a Yorkshire Terrier is 14 years, the device should viably be able 
to survive for the remainder of the dog’s lifespan, necessitating the ability of the device to survive 
in vivo for up to 7 years as a core objective. The device must not consequently fail due to fracture, 
the development of scar tissue, or the movement of the device from its deployment location. As 
such, ensuring that the device has a high enough fatigue strength and load strength to survive for 
7 years. The strength and number of cycles the device needs to survive depends on the overall 
design of the device. For example, a human tracheal stent needs to survive 3.3 kPa in tension and 
5.25 kPa in compression on a regular basis, and the standard nitinol stent can survive for 
10,000,000+ cycles of 33 kPa [11], [40]. Depending on the design, the values would need to be 
converted for use in dogs. Should the device break, invasive surgery would likely be required, 
which would lower the dog's quality of life. 
 The final primary objective is that the device must be biocompatible with the dog. For this 
application, it means that the device should interact favorably with the tracheal environment. The 
general statement with regard to biocompatibility is that the device should not be cytotoxic, or 
toxic to the cells around it. A major aspect of this is how tissue grows around the device. A layer 
of epithelial tissue should grow over the device, around 4-5 layers of cells, but under no 
circumstances can there be growth of granulation or scar tissue. If scar tissue were to develop near 
the device, it has the potential to cause device failure. The healthy growth of epithelial tissue would 
also enhance the ability of the device to withstand movement from its original position. The device 
should also not cause general inflammation of the surrounding tissue after implantation. This 
would only lead to an increased likelihood of scar tissue development. Finally, the body should 
not cause the enhanced degradation of the device. If the environment the device was placed in was 
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to start degrading it, then the lifespan of the device would decrease drastically, decreasing the 
overall fatigue and load strength. 
3.2.2 Secondary Objectives 
 The secondary objectives are more varied than the primary objectives. The first secondary 
objective relates more closely to the primary objectives than the other two. It is that the 
implantation of the device should be as minimally invasive as possible. This is to enhance the 
overall quality of life of the dog by not forcing them to go through a recovery period. The reason 
why this falls into secondary objectives and not primary is that if the implantation of the device is 
invasive, but it also essentially cures the tracheal collapse and there is no need for further action, 
then it would be superior to a minimally invasive device implantation that had to be repeated 
multiple times. The second secondary objective is that the device be compatible with current 
implantation methods. For something like a stent, it would mean implantation by catheter, or for 
something like extraluminal rings it would be surgery. This is simply to allow the use of the new 
device as soon as possible, without needing to teach vets a new implantation method. The last 
secondary objective is that it cost, at most, $1500. The current standard costs around $1,100, but 
if the new device is superior to the standard then a higher price won’t be an issue. The overall 
budget of the project for procuring materials, however, is only $650, so it will ideally be less 
expensive. As the subject of this project is adding to the current technology, and not replacing it, 
the ideal max price would be $400, as this adds with the current cost of the stent to the total of 
$1500. 
3.2.3 Functions 
 The design functions of the device are what the device must accomplish through its use. 
The first and most important function of the device is that it will reopen the collapsed trachea of a 
Yorkshire Terrier suffering from tracheal collapse. This is the fundamental function of the device, 
and the following functions are to ensure that the device can accomplish this function. The second 
function of the device is that will resist migration from its original location of placement. If the 
device were to move, then there is a possibility that the dog would be able to cough it up or 
experience tracheal tissue damage. The third function of the device is that it will resist fatigue 
caused by the movement of the trachea during normal motion. Should the device be unable to resist 
this fatigue, it would break and potentially cause more damage to the dog. Regardless, the device 
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would need to be removed and replaced before it was able to function correctly. The fourth and 
final function of the device is that it will be biocompatible, preventing the growth of granulation 
tissue around the device and enhancing the growth of healthy epithelial tissue. As granulation 
tissue grows, it would put excess force on the device, likely causing early fracture, and the growth 
of healthy epithelial tissue would enhance both the adhesion of the device to the tracheal and the 
overall biocompatibility of the device. 
3.2.4 Constraints 
 For the design of this device to treat dogs with canine tracheal collapse, there are several 
constraints that limit the project. Most obviously, there is limitation of budget. The device can cost 
up to $1500, with the developed coating costing up to $400, and the design team only has $650 to 
work with. There is also the limitation of testing material and equipment. Any material for testing 
will need to bought using the previously mentioned budget, and the number of cadaveric tracheas 
that the team has access to is limited by the number of donations that Tufts receives. The equipment 
the team has access to is limited to what can be accessed within the laboratory and additionally on 
the WPI campus. Finally, there is the constraint of time. The project must be complete by the end 
of March or early April to comply with graduation requirements. 
3.3 Design Requirements (Standards) 
 Several industry standards will need to be met in order to create a safe product. These 
standards also fall parallel with the overall project objectives. For this project, there are four 
standards set by the International Standards Organization (ISO) and the American Society for 
Testing and Materials (ASTM) that will need to be met. 
3.3.1 Industry Standards 
 The first ISO standard that needs to be met, ISO 10993-11:2017, which tests for toxicity in 
medical devices, is directly correlated with one of the primary objectives of this project, to make 
the device biocompatible. Meeting this standard ensures that any device that is implanted in a 
canine does not intrinsically cause harm by killing off the surrounding cells due to toxicity. The 
second ISO standard involved in this project is ISO 10993-1:2009 which is related to ISO 10993-
11:2017. This ISO standard also includes testing or auxiliary research to indicate that the device 
will not be harmful based on the material, manufacturing processes, geometric shape, contact area 
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with the body or its fluids, and its sterilization process. All of these standards were set in place to 
ensure that when a medical device is implanted, it has the highest possibility of not being harmful 
to its host. The last ISO standard that will need to be met by this project is ISO 11737-2:2009, 
which involves being able to sterilize a device before it is implanted. The inclusion of this ISO 
standard is based on the request of the sponsor of this project rather than necessity since the 
moment the device is opened to be implanted it would no longer be sterile. The one ASTM standard 
that will also need to be net for this project is ASTM F2063-12, which standardizes the use of 
nitinol for medical devices and implants. 
3.4 Revised Client Statement 
 After determining that the project should not concentrate on developing a new stent, it was 
refocused onto stent coatings. Instead, the client statement was revised to focus on determining a 
materials-based solution for existing stent biocompatibility and adhesion issues. The statement 
reads as follows: “The goal of this project is to develop and test coatings for canine tracheal stents. 
A successful stent coating will decrease scar tissue growth around the stent, keep the stent in place 
following implantation, and be applicable to stents that are currently available to surgeons.” The 
overall goal is to utilize coatings and processing techniques to improve the stent’s performance 
and longevity within the patient. The coating must be noncytotoxic, allow for positive cell 
adhesion to stay in place, and prevent the growth of excess scar tissue within the trachea. The 
developed coating must assist the stent in lasting for 7 years after implantation based on the average 
age of diagnosis (7 years) and the lifespan of Yorkshire Terriers (14 years). Overall, the coating 
must reduce the negative immune system response to the stent, assist with adhesion, and be 
compatible with the cells of the trachea. 
3.5 Management Approach 
3.5.1 Work Breakdown 
 Throughout A Term several important milestones have been met. To start this project, 
research was conducted in fields related to medical devices that treat tracheal collapse, the 
properties that make a device biocompatible, possible materials and coatings that could be used, 
and anatomical research on canines. The research on materials and coatings was then used to create 
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a list of possible options that could be used to create a device to assist a stent’s functions within a 
canine trachea. 
B Term served as the starting point for testing the list of suitable materials and coatings to 
establish which materials and coatings can cause cytotoxic responses, tissue irritation, and granular 
tissue buildup. Additionally, the project methods were refined to allow for additional testing and 
narrow down the candidate materials to determine the best final candidate. 
During C Term, the materials underwent additional verification testing to determine the 
final candidate for in-depth testing. Following the completion of the verification tests, the data 
underwent statistical analysis. This validation enabled the team to determine the successfulness of 
the project and allowed for the completion of a third draft of the report.  
The project candidate testing was finalized in the beginning of D-term. The report was 
finalized in D term with a deadline of April 26, 2018. The results of the project were presented on 
April 20, 2018 for WPI’s project presentation day. Following the completion of both requirements, 
the project was considered complete. 
3.5.2 Gantt Charts 
 
Figure 1: Fall Semester Work Breakdown 
Task to Be 
Completed 28-Aug 4-Sep 11-Sep 18-Sep 25-Sep 2-Oct 9-Oct 23-Oct 30-Oct 6-Nov 13-Nov 20-Nov 27-Nov 4-Dec 11-Dec
Project 
Objectives
Background 
Research
Introduction
Ch. 3
Ch. 4
Ch. 2
Report 1 Edits
Refine 
Methodology
Alternative 
Designs
Order 
Materials
Wire Coating
Mechanical 
Testing
Week
A-Term
Week
B-Term
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Figure 2: Spring Semester Work Breakdown 
3.5.3 Financial Considerations 
 The project team received a budget of $750. Access to the laboratory space cost $100 and 
granted access to basic cell culture laboratory supplies. The remainder of the budget purchased 
supplies for developing and testing stent coatings. Table 1 below displays the budget tracking 
sheet. 
  
Task to Be 
Completed 8-Jan 15-Jan 22-Jan 29-Jan 5-Feb 12-Feb 19-Feb 26-Feb 12-Mar 19-Mar 26-Mar 2-Apr 9-Apr 16-Apr 23-Apr 30-Apr
Wire Coating
Mechanical 
Testing
Refine Testing 
Protocols
Cytotoxicity 
Testing
Cell Adhesion 
Testing
Report 2 Edits
Determine 
Final 
Candidate
Ch 5
Final 
Validation
Statistical 
Analysis of 
Results
Ch6
Ch7
Ch8
Report 3 Edits
Final Draft of 
Report
Develop 
Project 
Presentation
Project 
Presentation 
Day
Week Week
C-Term D-Term
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Table 1: Budget Tracking Sheet for Project Items 
Component  Cost 
Lab space and basic supplies (acetone, chloroform, 5% acetic acid) $100 
Medical grade nitinol wire (72 in.) $44.79 
Chitosan (50g) $68.10 
PCL (Donated by Professor Marsha Rolle's Laboratory) $0.00 
PLLA (3g) $111 
Total $323.89 
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4.0 Design Process 
4.1 Needs Analysis 
4.1.1 Needs Criteria 
 The primary need fulfilled by this project is extending the lifespan of and enhancing the 
quality of life for Yorkshire Terriers that are suffering from advanced stage tracheal collapse. 
Tracheal stents, the primary current solution, tend to last for around 2 years, while Yorkshire 
Terriers are usually diagnosed with the disease at the age of 7 and live to 14 years of age. The 
alternative treatment method, extraluminal tracheal rings, is highly invasive and can lead to further 
complications. The tracheal stent’s short lifespan and lack adhesion and integration into 
surrounding tissue creates the need for a solution that is both more biocompatible and durable. 
4.1.2 Functions and Specifications 
 The objectives of this project, as previously mentioned, are durability, maintaining the 
tracheal opening, biocompatibility, compatibility of the device with current delivery methods, 
minimal invasiveness of the device, and the overall cost. These objectives were refined and 
weighed against one other to determine which were most critical for a stent to fulfill. The results 
of this comparison can be examined in Table 2 below.  
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Table 2: Pair-wise Comparison of Project Objectives 
Objectives 
Develop 
Stent 
Processing 
Resistant to 
Fatigue 
Demonstrate 
Cell 
Adhesion to 
Stent 
Coating/ 
Material 
Increase 
Longevity 
of 
Treatment 
Success 
Increase 
Tracheal 
Lumen 
Utilize 
Balloon/ 
Sheath 
Catheter to 
Minimize 
Invasiveness 
Develop 
Device For 
Current 
Procedures/ 
Equipment Total 
Develop Stent 
Processing 
Resistant to Fatigue 
X 0 0 0.5 1 1 2.5 
Demonstrate Cell 
Adhesion to Stent 
Coating/Material 1 X 0 0.5 1 1 3.5 
Increase Longevity 
of Treatment 
Success 1 1 X 0.5 1 1 4.5 
Increase Tracheal 
Lumen 0.5 0.5 0.5 X 1 0.5 3 
Utilize 
Balloon/Sheath 
Catheter to 
Minimize 
Invasiveness 0 0 0 0 X 0 0 
Develop Device 
For Current 
Procedures/ 
Equipment 0 0 0 0.5 1 X 1.5 
 
 The primary function of a device that corrects tracheal collapse in Yorkshire Terriers is to 
open and maintain the cross-sectional area of the trachea as close to 100% of the original area as 
possible. This would improve the overall breathing capability of a patient suffering from the 
disease. A coating applied to a stent must assist the stent in improving any mechanical and 
biological functions that are necessary in correcting tracheal collapse. The coating must 
additionally fulfill several other criteria, including resisting the forces that the coating would be 
subjected to in the dog’s trachea for approximately 7 years, resisting migration following the 
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deployment of the stent, and promoting the growth of healthy epithelial tissue while inhibiting the 
growth of granulation tissue.  
 The human trachea is exposed to forces 3.3 kPa in tension and 5.25 kPa in compression 
[40]. A dog’s neck is also able to rotate with more degrees of freedom than a human’s, so the 
values may be higher. However, there have been studies showing that the current gold standard 
for advanced tracheal collapse treatment, the nitinol tracheal stent, is capable of surviving 
10,000,000+ cycles of loading at 33 kPa [11].  
 The overall migration of any device that would be placed in the dog's trachea to correct 
collapse should be minimized. Any migration of the device increases the likelihood of irritation 
and may cause the dog to cough and dislodge the stent entirely. Increasing the radius of the stent 
to be slightly larger than that of the trachea reduces this risk [3]. However, dislodgement can still 
occur due to poor adhesion to the wall. As such, the coating should assist the stent in maintaining 
its deployed position and reduce irritation in the surrounding tissue. 
 Additionally, the last function of the coating is to increase the biocompatibility of the stent. 
For this project, this primarily means that the device should enhance the growth of epithelial cells 
over the stent while inhibiting the growth of granulation tissue. The growth of epithelial cells 
reduces the foreign body response from the surrounding tracheal tissue. This helps to prevent the 
growth of granulation tissue, which can fracture stents placed in the trachea, block the airway, or 
cause tracheal paralysis as it builds up over time. The growth of epithelial tissue also enhances the 
adhesion of the device to the tracheal wall. A layer about 4-5 cells thick would increase the overall 
adhesion of the device to the tracheal wall, decreasing the likelihood of dislodgment, and reducing 
the foreign body response.  
 Using the current gold standard as a base, the functions previously listed were enhanced 
by utilizing a designed and tested coating technology. As such, the coating itself does not need to 
provide these functions to the stent, granted that stent already produces the desired results. The 
coating itself doesn’t need to produce an increase in fatigue strength, instead it needs to be able to 
resist at least the same forces as the device. For increasing the lifetime, the coating should protect 
the device from bodily processes that would weaken its other properties, such as fatigue strength 
and biocompatibility.  
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4.2 Alternative Designs 
4.2.1 Non-Coating Alternatives 
 The direction that was chosen for this project was a coating for a tracheal stent, but there 
were similar options that could have been utilized. Specifically, the stents could have either 
undergone surface processing or anodizing. These are both processes that involved the direct 
modification of the stent’s surface, rather than the addition of new materials in a layer over the 
stent.  
 Surface processing is the modification of the surface of a stent to add ridges or grooves to 
the surface [41]. This increases the friction between the stent and the trachea, increasing the stent’s 
ability to grip the trachea. Grooves and ridges also provide places for cells to grow into, which 
will allow the eventual growth of tracheal tissue over the stent. Surface processing is generally a 
chemical or mechanical process, where either etching chemicals, milling implements, or lasers are 
used to remove material from the surface of the stent.  
 Anodization is the oxidizing of the surface of the stent, converting it from the pure metal 
state to the oxide state [42]. Oxides are much more resistant to corrosion than their metal 
counterparts, as they are technically already corroded through oxidization. This would extend the 
overall lifetime of the stent, as it normally corroded over time in the body. Oxides also provide a 
good base to hold drugs when layered with a polymer coating, and drugs could have been used to 
manipulate other properties between the stent and the trachea, such as cough suppressing and cell 
growth. Anodization is accomplished through the application of an electrical current to the stent 
while the stent is exposed to specific chemical reactants.  
 These non-coating alternatives were determined to be inefficient for the purposes of this 
project. Surface processing requires machining elements that were not available or required 
advanced training on said machines. Anodization was determined to not add or increase the 
properties that were being examined by this project, specifically biocompatibility. So, these 
options were ruled out, and coating options were examined.  
4.2.2 Coating Alternatives 
 Coatings were determined to be the optimal design process for the project. This conclusion 
was reached due the limitations that were on the project for time, resources, and skills. After that 
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decision was made, however, other options were considered. Most notably, the coating to utilize 
and the coating method.  
 To determine the coating to use, there were three options that had been found: A layered 
coating, a multistage coating, and a tracheal hardening coating. The layered coating is the simplest 
of the three, as it can be made with a single polymeric material [43]. This also makes it the most 
versatile. The layered stent can be made of multiple materials, it can be loaded with drugs, and it 
can include one to multiple layers. In the case of a drug eluting layered coating, the drugs would 
be loaded in the lower layers, and the upper layers would be used as the controlled release gate for 
the drug. The multistage release coating is like the layered coating, except that it is always a drug 
eluting coating and will always be made of more than one material [44]. The drugs will be within 
different layers of the coatings, and their control gates would be different polymers. This ensures 
that certain drugs are released quickly and early in the stents lifetime, while other drugs are 
released slowly and later in the stents lifetime. Depending on the polymers used, there can also be 
very specific triggers used to release the drugs, such as temperature or acidity. The third type of 
coating, the tracheal hardening coating, is purely theoretical on the part of this project. That is, it 
currently does not exist. The tracheal hardening stent would be a specific subclass of the previous 
coatings, one designed to reharden the softened trachea instead of delaying the eventual collapse. 
Of these three types of coatings, it was decided that the layered coating would be used for this 
project. This was decided as it was the most versatile, but also the most cost effective. Drugs were 
determined to be beyond the capabilities and budget of this project, which removed the other two 
types of coatings.  
 After choosing what kind of coating was needed, the method of applying said coating 
needed to be decided upon. Research pointed to three major coating methods: Dip Coating, Spray 
Coating, and Electrospinning. Dip coating is the simplest of the three methods. The stent is dipped 
in the dissolved polymer, and then the coating is allowed to dry [45]. Spray coating is similar 
except the coating is applied using a spraying device. This allows for much more control over the 
coating thickness [46]. Finally, electrospinning is the release of a small stream of polymer, 
depositing it in a random spinning pattern that fills out into a full coating as it is applied, and it 
dries [45] . It was decided that the dip coating method would be used for this project. The dip 
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coating method required no technology that needed to be acquired or learned, thus providing the 
most efficient option energy wise and cost wise.  
 Finally, the material that was to be used for the coating needed to be decided on. In an 
effort to conserve the project budget, three polymers were chosen to be tested. These polymers 
were PLLA, PCL, and Chitosan. PLLA is a common biocompatible polymer, used in numerous 
medical devices and the primary material used in 3D printing [47]. PCL is very similar to PLLA 
but tends to have a longer lifetime [48]. Finally, Chitosan is a biopolymer that is derived from the 
chitin in crab shells [49]. Research has found that there are specifically useful properties in 
chitosan, such as being biocompatible and generally mucoadhesive [49]. These three polymers 
were chosen to be tested against each other, and the polymer that would prove to be the best would 
be chosen as the final material for the polymer coating.  
4.3 Testing Methods 
 The needs outlined in Chapter 4.1 serve as the basis for the concept designs for the tracheal 
stent. These designs fulfill one or more of these individual needs: applied force, migration 
prevention, and biocompatibility. 
4.3.1 Surface Polymer Coating 
 The surface of the stent can be coated with a polymer to assist in adhesion to the tracheal 
wall. These modifications would allow for the stent to “grip” the tracheal wall itself, prevent 
migration, and increase the stent’s overall biocompatibility. The major options for polymer 
coatings that we will explore are poly-l-lactic acid (PLLA), polycaprolactone (PCL), and chitosan 
[47]-[49]. As for the method of coating, the team chose to use the dip coating method. The 
polymers and method were chosen primarily based on risk and cost. That is, after they met the 
requirements for biocompatibility. Other possible polymers were explored in the literature review, 
but the alternate methods of coating were spray coating, electrospinning, and polyelectrolyte 
multilayers. However, spray coating and electrospinning call for specialized equipment that was 
not accessible for this project, and polyelectrolyte multilayers require the polymers to have 
alternating positive and negative charges. Thus, we turned to dip coating, which can be done with 
forceps and an incubator. 
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The general method of dip coating is always the same: dissolve the polymer in a solvent, 
dip the subject being coated in the polymer solution, then allow the coating to dry. There are slight 
variations depending on the polymer, such as what solvent is used and if there is an additional dip 
following the drying of the coating. This dip in an additional fluid is used to ensure the solvent is 
completely removed from the drying polymer. The second dipping substance is generally a 
chemical that reacts with the solvent, pulling any remaining solvent out of the polymer coating. In 
general, any coating is at least washed with deionized (DI) water just to be careful. The solvents 
used in these methods are Chloroform for PLLA, Acetone for PCL, and 5% Acetic Acid (vinegar) 
for chitosan [47]-[49]. The PLLA and PCL were washed with DI water following drying, and the 
chitosan was dipped in a mixture of household ammonia and 75% isopropanol ethanol. Once the 
samples were coated and dried, they were imaged using a ZEISS AxioCam ERc 5s camera on a 
ZEISS Primo Vert microscope. The magnification was 20x to get a clear view of the sample and 
coating, and the phase should be Ph1/0.4. The general process is displayed below, in Figure 3. 
 
Figure 3: The Simplified Polymer Dip Coating Process 
4.3.2 Cytotoxicity Testing 
 The inflammatory response to foreign bodies in the trachea results in the growth of scar 
tissue.  The use of a coating in order to reduce inflammation and tissue irritation by increasing 
tissue adhesion would greatly improve the longevity of an implanted stent. However, while 
increasing tissue adhesion is important it is also critical to assess whether the material or coating 
has any possible cytotoxic properties associated with it. 
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 Any coating used must be noncytotoxic and allow for cell adhesion. The feasibility testing 
for this coating was conducted by using an MTT assay which is an ISO standard for testing 
cytotoxicity. This assay works by first seeding a known number of cells into various wells of a 96 
well plate and then adding tetrazolium dye to each well. The dye is then reduced into formazan by 
living cells which is a non-soluble byproduct of regular metabolic cell activity and has a purple 
color. After running the 96 well late through a spectrometer it is possible to measure the amount 
of purple dye present and correlate this with the amount of cell life present in each well. This data 
is then graphed, and a line of best fit is calculated to create a standard curve which allows for 
unknown values of cell life to be calculated. After the standard curve has been determined each 
material can be tested for cytotoxic properties by first creating leachates by placing a small coated 
stent sample into cell culture media and allowing any possible toxic chemicals to leach into the 
media. These leachates are then removed and used to feed cells in a 96 well plate that were seeded 
at 40,000 cells per well. After allowing the cells to incubate for 48 hours the tetrazolium dye was 
added allowed to incubate for another four hours. This plate is then run through a spectrometer 
and the absorbance values recorded are then compared to the known values in the standard curve 
to assess if any cytotoxic chemicals affected the cells. 
4.3.3 Force Testing 
 As Chapter 4.1.2 specifies, the stent must be able to withstand approximately 35,000,000 
loading cycles at 33 kPa over its lifetime. This is based on human data that was adapted to the 
more flexible dog trachea by increasing the necessary forces and loading cycles. The shape and 
structure of the stent allows for it to withstand more force. While this aspect of stent design is 
beyond the scope of this project, it is important to consider using flexible, fatigue-resistant shape-
memory materials as the structural basis for these stents. These materials are the gold standard for 
the canine tracheal stenting market, and any coating that is designed must be compatible with these 
materials, specifically nitinol. A dip coating for a nitinol stent must be able to also withstand 
cyclical loading with the same forces without degrading to be fully compatible with the stent. 
 To test the loading capabilities of a coating or material, two tests can be utilized: 
mechanical cyclic loading via a testing machine or loading using a simulated trachea. The 
mechanical cyclic loading would utilize the Instron 5544 and the corresponding Bluehill software 
to run long-term testing procedures for the required number of cycles and force level (35,000,000 
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at 33 kPa, or 40,000,000 when adjusted for any error). This data would be run through an analysis 
code in MATLAB to determine if there was any indication of failure or changes in mechanical 
loading response during the testing phase itself. The material or coated stent would then be 
physically examined to search for any defects or degradations on the surface. It would be 
considered a success if still intact and if the data did not show any indications of failure.  
Load testing using a simulated trachea would allow for the stent and coating to undergo 
the loading cycles while conforming to a trachea-like tube while testing. This type of testing would 
instead simulate the movement of the dog’s neck and trachea based on the ability for the dog to 
load its trachea. The flexibility data would likely be collected through examining cadaveric 
specimens for degrees of freedom in the neck and by utilizing observations from Tufts 
veterinarians on the number of times per day that dogs move their neck to the degree that shape 
change in the trachea would occur. While this would more realistically simulate the forces the stent 
would undergo, the apparatus would be less uniform and accurate regarding force levels and would 
require extensive testing prior to any testing on the stent and coating itself, since it must be 
constructed from scratch. The limited timeframe to complete testing makes designing and testing 
such a device difficult and less than ideal, making the traditional Instron testing the more favorable 
option. A basic 3-point bending test apparatus is displayed in Figure 4 below. 
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Figure 4: Instron 3-Point Bending Test Setup 
The feasibility testing itself would consist of 3-point bending testing. The 3-point bending 
test would position the expanded stent horizontally between two support spans while the Instron 
will use a third wedge to cyclically load the device in the center. The cycling would require 
approximately 35,000,000 cycles with 33kPa to best replicate the forces the stent will experience, 
which is not feasible with time and equipment restraints. Instead, lower forces and cycle lengths 
will be utilized. In both types of testing, the stent could be examined using an electron microscope 
both prior to and after testing, allowing for the microstructures of the material or coating to be 
validated. In a successful test, the material or coating will not fatigue, as it would inhibit the 
performance of the stent on the subject. 
During initial testing, individual coated and uncoated wires will be examined using 3-point 
bending testing. This will allow for the examination of the property changes of individual wires, 
which will then compose the whole coated stent as a system. 
4.3.4 Validation of Methods 
 The polymer coating method was tested first for chitosan, because it was the cheapest of 
the three polymers, then PCL, as it was dissolving in the acetone, and finally the PLLA, which 
failed to dissolve in acetone and thus required chloroform. All three polymers successfully 
managed to coat the nitinol wire samples, albeit with varying successes.  
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Figure 5: The Validation Images of the Chitosan Coated Samples (Bar = 50 microns) 
 The chitosan solution was 2 w% chitosan in 5% acetic acid. The solution was prepared 
over one hour and thirty minutes, being stirred at 40°C. The samples of nitinol wire were 2 inches 
in length, and their diameter was 0.006 inches (152.4 micrometers). The solution ended up being 
very viscous, similar to the consistency of honey. For the validation images, we were required to 
look for the errors in the coatings. Over most of the length of the samples, the coating is even and 
difficult to distinguish from the wire. However, there are small areas where the coating beads or 
appears to splinter, and it is those areas that we looked for to validate the coating method. As can 
be seen above in Figure 5, all four chitosan samples showed at least one small error in the coating 
that allowed us to recognize the coating. 
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Figure 6: The Validation Images of the PCL Coated Samples (Bar = 50 Microns) 
 The PCL solution was 5 w% in pure acetone. The polymer was incubated at 40°C in the 
acetone for around 24 hours, but most likely would have been fully dissolved by 6 hours. As 
acetone evaporates readily, the vial that the polymer was dissolved in was sealed with parafilm. 
The final solution was of a similar consistency to water. The nitinol wire samples were the same 
as with chitosan, 2 inches in length and 0.006 inches in diameter. As can be seen in Figure 6, the 
PCL coated samples provided much more obvious inconstancies than the chitosan. The more 
obvious inconstancies show a thicker coating, which can be good, but a thicker coating also could 
cause issues in testing but impacting the potential for mechanical bending. 
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Figure 7: The Validation Images of the PLLA Coated Samples (Bar = 50 Microns) 
 The PLLA solution was 5 w% in pure chloroform. The PLLA was first attempted to be 
dissolved in acetone but had not dissolved after almost a week of incubating at 40°C. In chloroform 
at 40°C, the PLLA dissolved within 24 hours. As with the PCL, this could probably be limited to 
6 hours and it would still be completely dissolved. The final solution was more viscous than the 
PCL solution, but less viscous than the chitosan solution. The nitinol wire samples were the same 
size as the other polymers, 2 inches in length and 0.006 inches in diameter. As can be seen in 
Figure 7, PLLA had the most obvious coating of all three polymers. The coating was visible with 
the naked eye in some cases. Looking at the samples on the right, one can clearly recognize the 
line between the wire sample and the polymer coating.  
 For all three of the polymers, multiple samples were prepared. This was to allow the other 
tests, the MTT assay and the mechanical testing, to be validated. The validation of the testing to 
  
  
 35 
 
be conducted on the Instron 5544 used a sample the selected wire, a piece of Nitinol SEA Black 
Oxide wire with a diameter of 0.006 inches and a length of roughly 2 inches. The selected strain 
rate and maximum displacement of the three-point bending test were 310 mm/min, and roughly 
12 mm respectively. The testing was planned to take place for a duration of 1,000 cycles while 
recording the force and displacement undergone by the wire. Figure 8 and Figure 9 below display 
the testing prior to loading and during loading respectively.  
 
 
Figure 8: The 3-Point Bending Test Prior to Loading the Wire 
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Figure 9: The Wire During Bending 
 The wire was able to be bent by the Instron without rolling due to a pair duct tape “grips” 
centering the wire on the support span. During the initial test, the wire was loosely adhered to the 
actuator, and in the secondary test the wire was not adhered. The results of the tests can be observed 
below in Figure 10 and Figure 11 below. 
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Figure 10: The Initial Results for the Bending Method Validation 
 
Figure 11: The Secondary Results for the Bending Method Validation 
 The first test failed after approximately 250 cycles, while the second test failed after 
approximately 300 cycles. In both cases failure occurred due to the wire slipping from the grips. 
While the data in test one appears to show observable force behavior, both tests produced data 
below the Instron’s resolution due to the load cell of the Instron 5544 not being designed for 
loading forces under 20N. Utilizing theoretical calculations was selected as an alternative to 
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physical mechanical testing due to the lack of an available load cell capable of detecting small 
forces. 
4.4 Final Design Selection 
 Based on the weighted project objectives matrix, the alternative designs can be compared 
against one another following testing. These tests, as described above, are coating integrity, 
cellular adhesion, cytotoxicity, and mechanical force testing. Additionally, secondary 
considerations are applied to coating cost and ease of application, as they are relevant in the clinical 
setting due to budget and equipment requirements for coating a stent. These tests each correspond 
to an objective, with fatigue resistance examined with mechanical force testing, adhesion of the 
stent coating examined with adhesion testing, biocompatibility examined with a cytotoxicity test, 
and coating integrity through examination under a microscope. The example weighted design 
matrix can be seen below in Table 3. 
Table 3: Blank Weighted Design Matrix for Candidate Materials 
 Bare Wire Chitosan PCL PLLA Weight 
Coating 
Consistency 
    2.5 
Manufacturing 
Concerns 
    0.5 
Mechanical 
Integrity 
    1.5 
Non-Cytotoxic     3.5 
Cell Adhesion     3.0 
Cost     1.0 
Total     12 
 
 With these objectives outlined and weighted, comparative testing on each alternative 
design can be performed, allowing for the best coating option to be verified with collected data. 
This data was scored based on the results of each individual test. The total score determined the 
most viable coating for use within canine tracheal stents.  
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5.0 Design Verification 
5.1 Coating Results 
After validating the testing methods, they were utilized on the samples that would later 
undergo the other testing protocols. All three materials produced a coating using the designed dip 
coating method, as seen in Figure 5, Figure 6, and Figure 7. After discussing and determining the 
needs of the other tests, it was determined that at least seven samples of each coated wire were 
necessary to successfully carry out the experimental methods. To factor in any errors that may 
have occurred, such as test failures or errors, an additional three samples for each polymer coating 
were made, bringing the total number of samples for each material up to ten.  
 
Figure 12: Materials Pre-Dissolution [a) Chitosan b) PCL c) PLLA] 
 
Figure 13: Materials Post-Dissolution [a) Chitosan b) PCL c) PLLA] 
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The three materials, chitosan, PCL, and PLLA, can be seen in their raw form in Figure 12 
and in their dissolved form in Figure 13. The chitosan, a flaky, white powder in its raw form 
(Figure 12a), becomes a yellow tinted fluid when mixed with vinegar at 40°C for two hours (Figure 
13a). The chitosan mixture is viscous, even when the solution is only made with 2 wt% chitosan. 
Even pushing the wt% up to 5% is enough to produce a fluid with such a high viscosity that it is 
nearly solid. The PCL, which is white pellets in its raw form (Figure 12b), becomes a clear fluid 
when dissolved in acetone at 40°C for 24 hours (Figure 13b). At 5 wt% PCL, the solution is fluid, 
which does not change when the wt% goes as high as 15%. The PCL also does not dissolve 
completely on its own, instead becoming a denser fluid in the acetone. 5 min of agitation, such as 
simply shaking the vial, followed by several hours of rest at 40°C is enough to completely dissolve 
the PCL. The PLLA, which is opaque crystals in its raw form (Figure 12c), becomes a clear fluid 
when dissolved in chloroform at 40°C for 24 hours (Figure 13c). The PLLA solution is the most 
viscous of the three at its chosen concentration, 5 wt%. Chloroform was required, as the PLLA did 
not dissolve in acetone after several days of exposure at 40°C.  
 
Figure 14: Wire in Solution 
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Figure 15: Fixing Solution. Water for PCL and PLLA, Ethanol and Ammonia for Chitosan 
Each sample was dipped into its polymer solution for two minutes (Figure 14), and the 
chitosan wire was additionally dipped into a fixing solution of ethanol and ammonia for five 
minutes. Only the Chitosan required a fixing solution (Figure 15) to create its coating, but the PCL 
and PLLA coatings used a wash of DI water to ensure that solvent wasn’t left behind on the 
coating.  
 
Figure 16: a) Holder to Assist Drying, Design by Washburn b) Wire Drying in Incubator 
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For the drying period, it was found during the validation testing that the binder clips 
holding the wires did not balance well on the vials. If the clips fell over during the drying period, 
it introduces additional errors in the coating. To resolve this issue, a holder for the vials and binder 
clips was designed using the PTC Creo CAD software and printed using PLA on a 3D printer 
(Figure 16a). 10 of these holders were printed so that a full set of samples could be made at once. 
The risk of imbalance wasn’t solved, but greatly reduced by the holders. The holders held the vials 
and the binder clips for the 24-hour drying period (Figure 16b).  
 
Figure 17: Imaging of Wire 
The imaging process remained the same for the candidate testing as that of the validation 
testing. A ZEISS AxioCam ERc 5s camera on a ZEISS Primo Vert microscope was used to take 
the images, and its default software was used to process the images and add 50 micrometer scale 
bars. The magnification used was 20x, and the phase was set to Ph1/0.4. The only difference 
between the imaging of the validation testing and the candidate testing is that the wire samples 
were left in their binder clips during the candidate testing (Figure 17). The samples were difficult 
to remove when placed in the dish alone, and this prevented damage to the samples when trying 
to remove them from the dish. 
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Figure 18: Deposition of Wire into Vial, and Removal of Holder 
After imaging, the coated wire sample was unclipped from the binder clip and deposited 
into the vial. To help maintain some degree of sterility, the vial holder shaft detaches from the base 
to allow easy removal of the vial (Figure 18).  
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Figure 19: Individual Chitosan Samples, n=10 (Bar = 50 microns) 
The success of the wire coating was determined qualitatively rather than quantitatively. 
The coating was successful if there was evidence found of a coating, but they were considered 
more successful if they were more evenly-distributed or thicker. The chitosan samples (Figure 19) 
all showed evidence of coating, so they were considered successful coatings. There were some 
samples that were considered more successful due to a more even coating (Figure 19a, b, e, g, h, 
j). An even coating was considered better because an uneven coating carries the risk of exposing 
portions of the sample while covering others. Conversely, there were some that were considered 
less successful due to unevenness of the coating (Figure 19c, d, f, i). In general, the issue that the 
chitosan samples had was evenness. Despite an even coating seeming to be applied after the initial 
dip, the coating would later prove to be uneven following the fixing solution bath and imaging. In 
some cases, the fixing solution turned the chitosan coating quite opaque, and it could easily be 
seen that the polymer coating beaded along the length of the wire.  
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Figure 20: Individual PCL Samples, n=10 (Bar = 50 microns) 
For the PCL samples (Figure 20), the overall coatings were extremely thin. This does not 
speak to the quality of the coating, as they were difficult to see using the power microscope 
available. It has been decided that for this project, the PCL samples are to be considered poorly 
coated. The PCL samples did not show much evidence at all of coating initially, and the images in 
Figure 20 needed to be taken after an additional coating of PCL was applied. The most apparent 
coatings can be seen in Figure 19a, d, e, f, h, and i. In all of these except Figure 19f, the coating 
appears in the image as a rough, uneven quality along the surface of the wire. Observing the wires 
during the dip process, there did not appear to be any coating applied after dipping, so most of the 
polymer dripped off when the wire was removed from the solution. 
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Figure 21: Individual PLLA Samples, n=10 (Bar = 50 microns) 
Overall, the PLLA samples (Figure 21) provided the most successful coatings in terms of 
adhesion to the wire. In fact, they provided samples that adhered so successfully that the coatings 
in some cases are too thick. Too thick of a coating could theoretically cause issues in the 
deployment of the coated stent. For this project, however, these coatings were considered 
successes. Very thick, very even coatings can be seen in Figure 21f, g, and i. Observing the samples 
during the coating process, the coatings could be visibly seen as the samples were transferred from 
the solution to their vials. In cases where the sample was tipped over and it bumped into the side 
of the vial, the PLLA dried the sample to the vial wall.  
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Table 4: Summary of Coating Information 
Uncoated 
Average 
Diameter 
(Microns)  
Chitosan 
Average 
Diameter 
(Microns) 
Chitosan 
Average 
Coating 
(Microns) 
PCL 
Average 
Diameter 
(Microns) 
PCL 
Average 
Coating 
(Microns) 
PLLA 
Average 
Diameter 
(Microns) 
PLLA 
Average 
Coating 
(Microns) 
122.75 135.43 6.33 128.07 2.66 181.41 29.33 
 
 
Figure 22: Bar Graph of Measured Coating Thicknesses, mean ± sd, n=14 
A summary of the coated wire diameters and their corresponding coating thicknesses can 
be found in Table 4 and in Figure 22. The measurements were made using ImageJ software, and 
then the final values were calculated using Excel. Each polymer was 14 samples measured, each 
with one image taken and four measurements per image. After measuring the coatings, the PLLA 
samples had the highest ability to coat the nitinol wire. As a contrast, the PCL samples had the 
lowest ability to coat the wire. Between the two materials lies chitosan, whose coating leans 
towards PCL rather than PLLA.  
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5.2 Manufacturing Concerns 
The difficulty of coating is largely dependent on the ability of the material to coat and the 
required safety equipment for creating the coating. The ability of the materials to coat can be seen 
in Table 4 and Figure 22. To summarize which polymers coated better, PLLA created the thickest 
coatings and PCL created the thinnest coatings. The safety of creating a coating is primarily a 
concern when using substances such as chloroform, as a fume hood is required, but applies to any 
solvent that produces unsafe fumes. However, the use of the fume hood does not maintain the 
sterility of the samples. The superior option in this would have been to use a sterile glovebox. As 
PLLA requires chloroform, it would thus be considered the most dangerous, while Chitosan is the 
least dangerous as it only requires vinegar. PCL comes in the middle with acetone as it's solvent. 
The coatings will be ranked from most to least safe based on safety concerns for preparing the 
coating, but also based on the ease of applying the coating to the stent. Since all candidates are dip 
coatings, the only difference in this regard will be the necessary number of repeated coatings 
required.  
5.3 Mechanical Testing Results 
Examining the mechanical property alterations that result from adding a coating to the 
individual stent wires allows for the viability of each coating to be examined. In most 
circumstances, where a mechanical testing apparatus of proper loading limits can be utilized, 3-
point bending testing provides data corresponding to the changes in force and stress corresponding 
to displacement and strain. However, initial testing of the super elastic wire presented forces below 
the Instron 5544’s resolution, in data that could not be used. With this limitation in mind, a theory-
based approach was taken to evaluate the effect that coatings have on the mechanics of the stent 
wire, and by extension the stent itself. 
Utilizing bending theory principles as a basis for these theoretical calculations, 
assumptions are made regarding the uncoated and coated wires. The wires are all assumed to be 
of equal length and wire radius, the coated wires are assumed to be cylindrical composites, and the 
radii throughout the coated and uncoated wires are assumed to be uniform throughout. The wires 
undergo 3-point bending, where a force is applied at the midpoint of the wire length while the wire 
is resting on supports. Figure 23 and Figure 24 below display the setup of the coated wires and the 
bending test respectively. 
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Figure 23: The Wire-Coating Composite 
 
Figure 24: The 3-Point Bending Test Setup 
The general 3-point bending equations and the area moment of inertias of solid and hollow 
cylinders largely serve as the basis for the comparison of the coated and uncoated wires. These 
will be utilized to further derive a relationship between the mechanical properties of the uncoated 
and coated wires. The equations utilized are as follows: 
𝑀
𝐼
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𝜎
𝑟
 
𝐼𝑤 =
𝜋
4
∗ 𝑟𝑤
4 
𝐼𝑐 =
𝜋
4
∗ (𝑟𝑇
4−𝑟𝑤
4) 
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Where the variables utilized are: 
 M = bending moment (N*m) 
 Iw = area moment of inertia of the wire (mm4) 
 Ic = area moment of inertia of the coating (mm4) 
 IT = total area moment of inertia of the wire and coating (mm4) 
 σ = applied stress (MPa) 
 rw = radius of the wire (mm) 
 rT = radius of the coated wire (mm) 
In theory, these values are utilized to calculate the relationship between the coated and 
uncoated samples. However, due to the composite nature of the uncoated wires, the modulus-
weighted area moments of inertia will be utilized. The calculations for these values are 
identical to their unweighted counterparts except for multiplying each component by a 
corresponding elastic modulus (E). The modulus-weighted equations are as follows: 
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤 = 𝐸𝑤 ∗ 𝐼𝑤 
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐 = 𝐸𝑐 ∗ 𝐼𝑐 
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑇 = 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤 + 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑐 
Where the Iweighted variables correspond to the composite or its individual components. The 
elastic moduli utilized were based on a literature search and approximations based on value ranges. 
Table 5 below lists the elastic modulus values utilized for the superelastic nitinol wire and the three 
coatings. 
Table 5: Elastic Modulus of Each Material 
Material Elastic Modulus (MPa) 
Superelastic Nitinol Wire [50] 58,000 
Chitosan [51] 6.3 
PLLA [52], [53] 1,000 
PCL [54] 156 
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 After finding the corresponding modulus-weighted area moments of inertia, the ratio of 
bending moments of the coated and uncoated wires will be examined by assuming that an equal 
stress is applied to each, setting up the following equation: 
𝑀𝑤
𝑟𝑤
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤
= 𝑀𝑇
𝑟𝑇
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑇
 
 After setting up the equation to solve for MT, the following relation is determined: 
𝑀𝑇 = 𝑀𝑤
𝑟𝑤 ∗ 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑇
𝑟𝑇 ∗ 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤
 
 If the magnitude of the coating’s elastic modulus is significantly smaller than that of the 
wire, the two modulus weighted area moments of inertia can be assumed to roughly equal. This 
assumption leads to a further simplification of the equation in case where the modulus of the wire 
is large, and the modulus of the coating is small: 
𝑀𝑇 ≅ 𝑀𝑤
𝑟𝑤
𝑟𝑇
 
 In this case, the ratio of radii is the primary factor that influences the ratio of the bending 
moments is the radius of the coating and the radius of the wire. Using the full set of equations, 
relationships between the wire and the 3 coatings were established. Table 6 below shows the results 
when assuming a uniform coating radius is utilized. 
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Table 6: Mechanical Calculations for Uniform Radii 
 
Uncoated Chitosan PCL PLLA 
Radius of Wire (in) 0.003 0.003 0.003 0.003 
Radius of Wire (mm) 0.0762 0.0762 0.0762 0.0762 
Radius of Coating (in) 0 0.004 0.004 0.004 
Radius of Coating (mm) 0 0.1016 0.1016 0.1016 
Estimated Modulus (MPa) 58000 6.3 156 1000 
    
 
I of Wire (mm^4) 2.64795E-05 2.64795E-05 2.65E-05 2.65E-05 
I of Coating (mm^4) N/A 5.72088E-05 5.72E-05 5.72E-05 
I Total (mm^4) 2.64795E-05 8.36883E-05 8.37E-05 8.37E-05 
    
 
Modulus Weighted I Uncoated (MPa * 
mm^4) 
1.535810952 1.535810952 1.535811 1.535811 
Modulus Weighted I Coated (MPa * mm^4) N/A 1.536171368 1.544736 1.59302 
Ratio of Bending Moments (Mc = x*Muc) 1 0.750176006 0.754358 0.777937 
Ratio of Radii 1 0.75 0.75 0.75 
 
 The above table shows that the coatings perform similarly when they are the same radius. 
The ratio of radii is best utilized as a numerical check, as it is the ratio of bending moments if the 
modulus-weighted area moment of inertia of the coating is negligible. The coating with the 
bending moment closest to the original is PLLA by about 2% over the other coatings examined. 
However, the coatings will not have uniform radii due to their coating thicknesses and ability to 
adhere to the stent wire. In Table 7, the coatings were examined using estimated radii from coating 
testing. 
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Table 7: Mechanical Calculation for Observed Radii 
 
Uncoated Chitosan PCL PLLA 
Radius of Wire (mm) 0.0614 0.0614 0.0614 0.0614 
Radius of Coating (mm) N/A 0.0677 0.0643 0.0907 
Estimated Modulus (MPa) 58000 6.3 156 1000 
    
 
I of Wire (mm^4) 1.114E-05 1.114E-05 1.114E-05 1.114E-05 
I of Coating (mm^4) N/A 5.369E-06 2.277E-07 4.202E-05 
I Total (mm^4) 1.114E-05 1.651E-05 1.342E-05 5.316E-05 
    
 
Modulus Weighted I Uncoated  
(MPa * mm^4) 
0.646 0.646 0.646 0.646 
Modulus Weighted I Coated (MPa * mm^4) N/A 0.646 0.647 0.688 
Ratio of Bending Moments (Mc = x*Muc) 1 0.906 0.955 0.721 
Ratio of Radii 1 0.906 0.955 0.677 
 
 In this case, PCL is the closest to the original bending moment, due to its small coating 
radius. Chitosan performs as expected with the ratio of radii, and PLLA, while having the lowest 
ratio of bending moments, performs better than the ratio of radii. Knowing the ratios of the bending 
moments of the coated and uncoated wires allows for approximations of the applied forces to 
occur. Utilizing the derived form of the force applied to a beam, the following equations are 
known: 
𝑀 =
𝜎𝐼
𝑟
 
𝐹 =  
4𝑀
𝐿
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 Assuming the applied stress is 33 kPa, knowing the length is 2 in, and determining the 
radius and area moment of inertia above, the force required to reach 33kPa in the uncoated wire 
can be determined to be 9.0315E-07 N. This is far below the Instron’s load cell and verifies the 
lack of observable data returned after testing. Knowing the ratios of the bending moments of the 
coated and uncoated wires, it is determined that it will take approximately 90% of the uncoated 
force for chitosan, 72% of the uncoated force for PLLA, and 96% of the uncoated force for PCL 
to reach the same stress. While these force values are still in the 10-7 range, it does alter the 
mechanical properties. With this in mind, the theoretical data should be weighed less than other 
testing components due to uncertainties in the properties of a coated stent, since these calculations 
considered individual wires. 
5.4 Cytotoxicity Test Results 
The MTT assay was done using 3T3 mouse fibroblast cells in DMEM basal media with 
penicillin-streptomycin, glutaMAX, and fetal bovine serum added to it. This standard curve was 
run as a proof of concept experiment to show that the number of cells seeded has a direct effect of 
the light absorbance recorded. This experiment was also done to identify the range for which this 
assay is valid. Based on the data gathered seeding anywhere from ten to fifty thousand cells after 
48 hours of growth falls within the valid range for this assay. The data generated from this assay 
was then used to create a line of best fit which was later used to find the number of living cells 
detected after they were exposed to various leachates as shown in Figure 25.  
 
Figure 25: Creation of Leachates for MTT Assay 
This standard curve is displayed below in Figure 26. 
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Figure 26: Standard Curve for MTT Assay 
The results from the MTT assay are shown below in Figure 27. These results show that 
little to no cell death occurred after seeding the cells at about 40,000 cells per well originally. Some 
of the variation can also be attributed to human error when seeding the cells originally. The lack 
of cytotoxicity is also evidenced by the lack of increased cell death in the 14-day leachates. 
 
Figure 27: Coating Comparison Based on MTT Assay 
5.5 Adhesion Testing Results 
 The uncoated and coated wires underwent cell adhesion testing to determine if the addition 
of a coating increases a stent’s ability to adhere to tissue. To perform this type of testing, a non-
adhesive well was utilized, preventing the cells from sticking to anything but the selected wire 
sample. Additionally, said well was designed with a V-shaped notch to allow gravity to increase 
the chances of the cells settling directly on to the wire, as opposed to evenly spread around the 
well, lacking contact with the wire sample [55]. 
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 Agar was selected as the material for these wells, due to it being non-adherent to cells. In 
the initial well design, the triangular prism-shaped strips of PDMS were utilized to leave a v-
shaped impression on the agar. This PDMS was made utilizing a 10:1 ratio of Sylgard base and 
curing agent, which was thoroughly mixed, poured into a petri dish and then degassed for 
approximately hour. After degassing, the PDMS was cured in an oven for an hour at 60°C, 
removed and allowed to cool. Following this, the PDMS was cut into triangular prism-like strips 
approximately three fourths of the length of a 6-well plate well with a razor blade. Alongside these 
PDMS strips, a roughly 2% agar solution was made using 500mL of de-ionized water and 11g of 
agar. This solution was placed in the autoclave in a glass bottle with a loose cap (to prevent the 
pressure from shattering the bottle) alongside an autoclave pouch containing the individual PDMS 
strips along with forceps and a spatula to assist with the placement of the strips into 6-well plates. 
 After laying the strips along the bottom of the wells, 10 mL of warm hot agar was 
transferred into each well using a pipette controller. The agar was cooled in a sample refrigerator 
and removed when the agar was a solid gel. A spatula was utilized to flip the well over and remove 
the PDMS strip, completing the wells. They were stored in the 6-well plates in the refrigerator 
while being inverted to prevent any unwanted bacterial growth from occurring. Figure 28 displays 
the wells as they were cooled into a gel in the refrigerator and Figure 29 displays the results of the 
well molding. 
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Figure 28: Agar Wells After Pipetting Agar into 6-Well Plate 
 
Figure 29: Agar Wells After Flipping and Removing PDMS 
 The second well design was nearly identical to the original, but it utilized 3D printed 
polyethylene terephthalate glycol-modified (PETG) mold to accurately replicate PDMS strip sizes 
in every sample. The mold was printed on a Wanhao i3 3D printer with micro-swiss all metal 
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hotend, and used MakerGeeks 1.75mm HD Blue Glass PETG filament. The advantage of using a 
mold is that it ensures that each strip is of uniform length and depth, preventing any human error 
from occurring while cutting PDMS to approximate sizes. This 3D printed mold is displayed below 
in Figure 30 below. 
 
Figure 30: 3D Printed PDMS Mold, Designed by Washburn 
PDMS was poured into the mold until about 1-2mm was left unfilled per mold 
compartment. This was degassed for 30 minutes, then cured in the oven for 1 hour. The resulting 
PDMS gels were autoclaved and underwent the same process as the individually cut PDMS 
notches. 
Media was added to each used well of a six well plate along with the agar V-shaped mold 
containing a wire sample so that both the mold and wire could equilibrate with the media. This 
allowed for adhesion testing to occur following cell seeding. Figure 31 displays the wells following 
loading with media. 
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Figure 31: Wells Following Media Loading 
After seeding cells onto the wires using these molds Hoechst dye was added to make the 
cells visible. There were issues imaging the wire samples. The thick layer of agar scattered the 
light from the microscope which made it nearly impossible to properly image the samples. The 
wire samples were removed from the molds, but few cells remained after being pried up out of the 
wells and placed onto glass coverslips. It was also found that the chitosan polymer took up the 
Hoechst dye that was used to stain the cells which made it impossible to tell the difference between 
any possibly adherent cells and the polymer coating as seen in Figure 32. 
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Figure 32: Round One Cell Adhesion 
A second round of testing was done without the agar molds to improve imaging and with 
GFP cells to make the cells fluoresce green. However, similar issues occurred. While cell 
accumulation around each of the wires is visible each of the polymer coating shown in Figure 33 
it is difficult to tell if these cells are truly adherent to the wires or just accumulating around them. 
It was also noted that even when the cells were spun out of the Hoechst dye before they were 
seeded onto the wires the chitosan sample still fluoresced which indicates that it is auto fluorescent. 
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Figure 33: Adhesion Testing Results 
5.6 Cost Analysis 
 The cost to apply each coating is based on the amount of each polymer required per 
complete dip coating, approximated utilizing known prices per quantity of polymer. This, in 
addition to any solvent cost, will determine which coating is the least expensive to utilize, and will 
be ranked accordingly. These costs can be observed numerically in Table 8 and comparatively in 
Figure 34 below. 
Table 8: Production Cost of Coatings Per mL 
 Chitosan PCL PLLA 
Cost per mL of 
Polymer Solution 
$0.03 $0.43 $3.33 
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Figure 34: Bar Graph of Production Cost per mL of Polymer Solution 
In summary, chitosan is the least expensive coating to produce per mL, while PLLA is the 
most expensive to produce per mL of solution.   
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6.0 Final Design and Validation 
6.1 Methodology Summary 
6.1.1 Coating Integrity Methods 
  To coat a nitinol wire sample in a chosen polymer, the polymer must first be dissolved in 
a solvent. Some polymers require specific solvents, but acetone and chloroform are commonly 
utilized. The mass of polymer used depends on the desired mass% for the final solution. For 
example, a 10% w/v solution with a volume of 100 mL would use 10g of solid polymer and 90 
mL of solution. Varying the mass% will change the final properties of the solution, with the 
viscosity of the solution increasing at higher % w/v values. The solubility may be different for 
each polymer. For the polymers used in this paper, the solid PCL and PLLA could be dropped into 
their solvents, left over night in a 40C incubator, and they would be dissolved in the morning. PCL 
also needed to be shaken thoroughly at the end to ensure even mixing. Dissolving chitosan was 
more difficult. The solid chitosan dissolves into a very viscous solution, so any undissolved 
polymer becomes more difficult to dissolve as times goes on. To solve this, the chitosan needed to 
be stirred while in the Acetic Acid, after which the solution would be ready in about two hours. 
Once the polymer solution was prepared, one must also prepare any additional solutions needed. 
An example of this would be chitosan from the experiments represented in this paper. Chitosan’s 
solvent was 5% acetic acid, which does not readily evaporate as acetone and chloroform do. So, 
the solvent needed to be reacted out of the solution once it has been applied to the sample. For 
chitosan, this second solution, noted as the fixing solution, was a mixture of ethanol and ammonia.  
 Once the solutions had been prepared, the wires were dipped into the solution. In the 
experiment from this paper, the wire samples were dipped into the polymer solutions for two 
minutes. Additionally, the chitosan samples were then dipped into the fixing solution for five 
minutes. Following dipping, the samples were placed into prepared vials, using small binder clips 
to keep them suspended while they dry. The vials that were used tended to be unstable, so a tube 
and base complex was designed and 3D printed to keep the vials from falling while they sat in the 
incubator at 40C. The drying process was complete in about 24 hours. When the samples were 
completely dry, they needed to be dipped one more time to help removed any excess solvent. For 
PCL and PLLA, this dip was in deionized water. For chitosan, the samples needed to have one 
more dip in their fixing solution.  
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 As soon as the samples were dry, they were ready for imaging. The wire samples were put 
into a petri dish for the imaging process. The samples tended to get statically stuck to the dishes, 
so the binder clips were left on the samples for easy removal. The samples were imaged at 20x 
magnification, and if the coating was not even the samples were searched for any evidence of a 
coating before the image was recorded. Once the samples were imaged, they were returned to their 
vials, released from their binder clips, and capped off so that the samples would be ready for the 
next experiment they would be used in.  
6.1.2 Application Concerns Methods 
 The application concerns become more of an analysis of properties of the polymers and 
their solvents. The focus was more on the analysis of the polymers ability to coat the wire samples. 
For chitosan, it could a coating averaging around 6 microns thick, but the coating was overall very 
uneven. The polymer tended to bead on the wire rather than maintain an even coating. For PCL, 
the polymer could create an even but thin coating. For PLLA, the coating tended to be very even 
and thick, instead. The importance of the thickness of the coating depends on the purpose of the 
coating. As the wire samples were representing a canine tracheal stent, where a thick coating could 
impair the stents ability to shrink and expand, a thin coating would be preferred.  
 For the solvents, the application concerns came mostly down to safety. Exposure to acetone 
and acetic acid is common, in the form of nail polish remover and vinegar respectively, so they do 
not pose a hazard for human operators. However, chloroform has been tested and found to be toxic 
and carcinogenic with long term exposure. This could be a danger to those applying the coating 
regularly if proper safety conditions are not met.  
6.1.3 Mechanical Integrity Methods 
 As examined in Chapter 5, the normal 3-point bending methods for solid samples (utilizing 
the Instron 5544) was not applicable to the stent wire samples due to their size and ability to freely 
bend. This resulted in the need to derive a theoretical calculation to examine the overall impact 
that adding a coating has on the ability of the wire to resist forces applied to it. This was done by 
utilizing both the general bending moment calculations for an uncoated and coated wire sample, 
setting all variables equal to an arbitrary stress value, along with implementing the modulus-
weighted area moment of inertia to better understand the magnitude of the contribution that the 
coating has on the mechanical properties of the individual wires.  
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Adding a coating to the stent wires may result in a change in the mechanical integrity of 
the wire itself. In general, simple 3-point bending is utilized to relate changes to force and 
displacement based on the coating added to the wire. However, due to the small size of the 
individual wires examined, the mechanical testing device, an Instron 5544, was unable to record 
the force applied to the wire because of the difference in magnitude between the force and the load 
cell resolution for measuring forces. Theoretical calculations are utilized to estimate the 
mechanical effects adding a coating has for a stent wire. 
 The bare wire is assumed a solid cylinder of radius rw, while the coating is assumed to be 
a hollow cylinder with an outer radius rT and an outer radius or rw, where rw is the radius of bare 
wire and rT is the radius of the wire and coating together. A visual representation of the composite 
consisting of the wire and coating can be seen below in Figure 35. 
 
Figure 35: Wire and Coating Composite 
The modulus-weighted area moments of inertia were derived by multiplying the composite 
components, the wire and the coating, by the appropriate elastic modulus. The coated wire required 
the summation of the two components, while the uncoated wire utilized the wire modulus only. 
After deriving the modulus-weighted area moments of inertia, the general bending moment 
equation is set up for both the uncoated and coated wires. Following this, the applied stresses are 
set equal, allowing for the following equivalence statement to be derived: 
𝑀𝑇
𝑟𝑇
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑇
= 𝑀𝑤
𝑟𝑤
𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤
 
𝑀𝑇
𝑀𝑤
=
𝑟𝑤 ∗ 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑇
𝑟𝑇 ∗ 𝐼𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑤
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 This ratio of total (wire and coating) bending moment and bare wire bending moment 
determines difference in bending moments between the two samples for the same applied pressure. 
This ratio correlates to the force applied to either wire sample, where if the ratio is less than 1, then 
it will take less force for the coated wire to reach the same stress as the uncoated wire, while if the 
ratio is greater than 1, then it will take greater forces on the coated wire sample to reach an 
equivalent stress as the uncoated wire. This is essentially determined by the following ratio: 
𝐹𝑇 =
𝑀𝑇
𝑀𝑤
𝐹𝑤 
 With this relation established, the mechanical effects of applying a coating to a wire can 
be examined theoretically. While this method allows for simple verification, utilizing a mechanical 
testing device with a sensitive load cell or larger wire samples is recommended where possible. 
6.1.4 Cytotoxicity Methods 
The possible cytotoxic properties of each of the materials used was assessed by using an 
MTT assay. First a standard curve of known values of live cells was evaluated to find a line of best 
fit that could then be compared to unknown values in order to find their cell viability. The 
experimental cells were made by first soaking each type of wire sample in media for either 7 or 14 
days. The leached media was then removed and used to culture the experimental cells. Overall this 
test showed that none of the materials tested were cytotoxic. 
6.1.5 Cell Adhesion Methods 
The tissue adhesion properties of each of the materials was tested by using cells that were 
cultured with wire samples. However, after running into problems with imaging the wire samples 
literature was referred to in order to figure out the adhesive properties of each polymer [29]. 
6.1.6 Cost Effectiveness Methods 
 The cost effectiveness of each polymer was found by determining the cost of producing an 
mL of the polymer solution. To perform this calculation, the cost of the polymers per gram and 
the solution concentrations, in grams of polymer per mL of solution, were found. These values 
were then multiplied together to calculate the cost per mL of solution. For the polymer candidates, 
the cost per mL was found to be $0.03 for 2% Chitosan, $0.43 for 5% PCL, and $3.33 for 5% 
PLLA. 
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6.2 Summary of Data Analysis 
 Once the testing methods had been carried out, the data could be analyzed, and the results 
compared. For the coating consistency, the results showed that chitosan produced a coating of 
about 6.5 microns thick, PCL produced a coating about 3 microns thick, and PLLA produced a 
coating about 30 microns thick. These values were an average, and each of them had a standard 
deviation that was larger than the average value. PCL was considered to have a coating that was 
too thin, and it would likely not withstand the stresses of standard canine tracheal motion. PLLA 
had the opposite problem, where the coating was decided to be too thick, which would impact the 
ability of the stent to deploy. Thus, the chitosan coating was found to be the preferred coating. 
 For manufacturing concerns, it was decided that PCL was lacking due to its difficulty of 
producing a coating. Likewise, PLLA was also found lacking due to too great of an ability to form 
a coating. Also, PLLA requires the use of a toxic solvent, chloroform, which is carcinogenic after 
long exposure. This would pose a danger to anyone operating equipment to coat the stents. Thus, 
we were left with chitosan, as it’s solvents and other necessary chemicals are all readily available 
in a department store. 
 Analysis of the mechanical integrity found that both chitosan and PCL had very little effect 
on the mechanical strength of the nitinol wire. The applied force needed to generate a certain stress 
in the chitosan and PCL coated wires was only about 90% of the force that would needed to 
generate the same stress in an uncoated wire. PLLA, on the other hand, caused a decrease in the 
required force to produce an equivalent stress by about 30% of the force required for an uncoated 
nitinol wire.  
 Cytotoxicity testing found that all of the polymer coatings were as non-cytotoxic as an 
uncoated nitinol wire. The comparison between the polymers found no difference, and the 
comparison within each polymer between the samples that had been leeched for 7 days and those 
that had been leeched for 14 days found no difference. That is, there were 40,000 cells seeded in 
the leachates from the polymer cells and the bare wires, and there was no significant cell death 
caused by any of the leachates.  
 As the cell adhesion testing ran into a large compliment of errors, the data was decided to 
be unusable in the state it was. As such, with the time available to the team at that point, it was 
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information from published materials was used to provide these results. From these published 
materials, it was found that chitosan proved to be mucoadhesive, which would be beneficial in the 
canine trachea. PCL and PLLA, however, both showed results that their application as coatings 
decreased the overall cell adhesion. As such, chitosan was decided to be the preferred material. 
 Finally, an analysis of the costs associated with the production of the polymer solutions 
was done. From this analysis, it could be seen that chitosan was the most affordable of the three 
polymers, with PCL coming in a close second place and PLLA trailing far behind in third.  
6.3 Final Candidate Selection 
Following the completion of all tests, the results were examined using the weighted design 
matrix. The candidate coatings were compared against one another and against the bare nitinol 
wire (gold standard) with the following rating values: 0 – meets gold standard; +1 – exceeds gold 
standard; -1 – falls below gold standard. The weight of each test was determined based on the 
importance of each feature to the overall design. These weights were then multiplied against the 
score values for each candidate in each test, and the highest overall score determined the selection 
of the final candidate coating. Table 9 below illustrates the score calculations. 
Table 9: Final Weighted Design Matrix for Candidate Materials 
 Bare Wire Chitosan PCL PLLA Weight 
Coating 
Consistency 
0 +1 -1 -1 2.5 
Manufacturing 
Concerns 
0 0 +1 -1 0.5 
Mechanical 
Integrity 
0 0 0 -1 1.5 
Non-Cytotoxic 0 0 0 0 3.5 
Cell Adhesion 0 +1 -1 -1 3.0 
Cost 0 +1 -1 0 1.0 
Total 0 +6.5 -6.0 -8.0 12.0 
 
 As can be seen, the chitosan coated wire performs better than the PCL and PLLA coated 
wires. The chitosan dip coated stent was chosen to be the final proposed candidate for this project. 
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This candidate produced approximately a 6.5-micron coating. Additionally, manufacturing the 
coated stent with this polymer presents minimal difficulties due to its non-toxic solvent, acetic 
acid. However, the coatings produced were uneven in some cases, but utilizing a modified dip 
coating procedure or a mechanized process could help to ensure that future coatings are even. The 
coating increased the mechanical forces applied to the stent by approximately 10%, which 
corresponds to the ratio of the uncoated and coated wire radii. This force difference is expected as 
the total radius increases, and it performs better than PLLA’s ~28% difference. When looking at 
cytotoxicity, chitosan performed no better than the other samples. However, all the samples 
showed no evidence of any cytotoxicity. After examining the per mL cost of each coating solution, 
chitosan was determined to be the least expensive, presenting the best value for a veterinarian or 
manufacturer looking to apply the coating as a post-production modification. 
The final candidate was selected by weighing what qualities were the most important for a 
successful product and then comparing each of the possibilities to a bare nitinol stent which is 
currently the gold standard. From this comparison it was clear that a chitosan coated nitinol wire 
was by far the best choice. A chitosan coated wire is non-toxic, does not hinder the mechanical 
properties of the nitinol wire, does not require the use of toxic chemicals during its fabrication, is 
tissue adhesive, and is the most affordable option that was assessed. ISO standards were considered 
when deciding what properties needed to be considered to ensure that the final candidate choice 
was biocompatible. The ISO standards that were focused on were for cytotoxicity, implantation, 
and degradation. The MTT assay was used to address any cytotoxic concerns. Adhesion testing 
and literature was used to ensure a positive implantation with reduced amounts of inflammation 
and scar tissue build up. Finally, the degradation properties were assessed using mechanical 
equations. In order to market this device, the adhesion testing would have to be improved so that 
literature did not have to be relied upon. Manufacturing considerations would also have to be taken 
like packaging the coated stent in sterile packaging. 
6.4 Impact of Final Candidate 
 When creating a new method or apparatus, its impacts on the world at large must be 
theorized before public release. These impacts can range widely, from economic and 
environmental all the way down to manufacturability and sustainability. To ensure that the 
variation is making positive impacts, or may potentially in the future, all influenced aspects need 
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to be considered during the production and experimentation process. These potential impacts 
influenced the development of our final candidate coating.  
6.4.1 Economic 
 Canine medicine is expensive. As such, minimizing the cost of medical treatment allows 
for dog owners to be able to consider better solutions to medical issues experienced by their dogs. 
The application of this coating may reduce the chances of stent failure due to fracture or immune 
response. While the coating will result in an increase to the stent price, the need for emergency 
surgery and stent replacement will be reduced upon improving the coating to market level, 
resulting in an overall decrease in the price sustained tracheal collapse treatment. This will in turn 
allow for the procedure to be more economically accessible to dog owners due to increased success 
rates. 
6.4.2 Environmental 
 The new canine tracheal stent coating should enhance the lifespan of stents, so there will 
need to be less disposal of broken stents. The polymer used for the final coating design, chitosan, 
is derived from crab shells. In the case where the coating becomes commonly utilized in tracheal 
collapse treatment and for other purposes, then overfishing of crabs and other shellfish to harvest 
chitosan could become a potential problem. This may also allow for a reduction of waste if these 
shells are obtained from sources that primarily utilize the meat of these crustaceans. The only 
significant environmental impact could come from the disposal of the solvent and chemicals used 
during the coating process. While there are varying levels of toxicity among them, all of the 
solvents utilized would be considered hazardous waste. Inappropriate disposal of said chemicals, 
such as unregulated dumping into water sources, could lead to major ecological impacts and 
organism death. 
6.4.3 Societal  
 Dogs are popular companion animals globally. It can be detrimental to the mental state of 
dog owners to witness their dogs suffer from or die of medical complications. By enhancing the 
treatment of a disease that reduces dogs’ quality of life, these dogs can sustain their health and live 
longer. A treatment such as this will likely be viewed favorably by the general populace. 
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6.4.4 Political 
 The new chitosan coating for canine tracheal stents falls within the current regulation for 
medical stents, so there should not be political ramifications from the coating’s release.  
6.4.5 Ethical 
Canine tracheal collapse results in the reduction of the quality of life of dogs. Canine 
tracheal stents exist to reduce the effects of this condition, and in turn improve the dog’s quality 
of life. However, the occurrence of stent failure results in increased distress, emergency surgeries 
to retrieve and replace the faulty stent, and an additional recovery period following the ordeal. 
With an improved stent coating, the likelihood of failure occurring decreases, allowing for less 
suffering and distress to occur following surgery. 
6.4.6 Health and Safety 
 Dogs tend to contract canine tracheal collapse around 7 years-of-age on average. As many 
of the dogs that can suffer from this condition have lifespans up to 14 years, tracheal collapse can 
reduce their lifespans significantly. The failure of a stent would additionally cause serious harm to 
the dogs affected. As such, the introduction of a new coating for canine tracheal stents that can 
extend the lifespan of these stents, reducing the chances of failure and allowing for extended 
treatment of tracheal collapse, would increase the health of the dogs affected by canine tracheal 
collapse overall.  
6.4.7 Manufacturability 
 This new coating should be easy to recreate and apply to current stents in a manufacturing 
setting. This is supported by its production using standard laboratory equipment, suggesting that 
mass production would not pose issues. In a manufacturing setting, the polymer solutions would 
be able to be produced in mass and machines would be able to dip more stents at a faster rate than 
a standard laboratory technician can. The simple process would require very little additional work 
to move the production of the coating to a manufacturing setting. Additionally, manufacturing 
machinery could ensure consistent quality of coatings with precision not attainable without 
machine assistance. 
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6.4.8 Sustainability 
 This new coating requires minimal energy input to produce. A stirring mechanism is 
required to prepare the chitosan solution, and an incubator or oven is required to dry the coatings. 
Aside from these energy uses; the new coating has minimal impact on renewable energy and 
energy consumption.   
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7.0 Discussion 
7.1 Analysis of Results 
7.1.1 Coating Integrity 
 The primary mechanical processing aspect of this project is the application of the chitosan 
coating to the nitinol wire.  If a coating does not stick, or does not coat evenly, then it may not 
provide the beneficial properties like a normal coating would. As such, there are many aspects of 
this process that can vary by individual sample. These aspects are concentration, preparation, and 
speed of removal from the solution.  
 Concentration is the most basic aspect of the coating process. Most polymer solutions are 
made using a percent weight per volume (% w/v) value, which represents the percentage of the 
total mass of polymer in the solution. In the development process of the chitosan coating, the mass 
percent used was 2% w/v, which was a value obtained during the literature review [49]. This 
produced a very viscous solution. At a later point in the process, an additional 5% w/v solution 
was accidentally produced. This resulted in a solution that was almost completely solid. This large 
difference in results between two % w/v values is likely due to the nature of chitosan as a polymer 
itself. Chitosan is a biological polymer derived from the chitin in crab shells. Crab shells are the 
crabs’ natural defense against predators, and the strength of the chitin that makes up the shells is 
integral to this. Chitosan retains some of chitin’s properties, most notably its random amorphous 
form in its polymerized state. This amorphous quality allows the chitosan solution to have higher 
viscosity at lower % w/v of solid polymer.  
The polymer preparation method could have caused this viscosity change. Chitosan 
requires 5% acetic acid to dissolve and doesn’t react to acetone or chloroform like PCL and PLLA. 
However, 5% acetic acid is a significantly weaker solvent than either acetone or chloroform. There 
are other aspects of preparation, though. Unlike PCL and PLLA, chitosan required stirring for the 
entirety of its dissolution, or the solution would become too solid for it to be reliably used to coat 
the samples. The duration of mixing, which was minimally 2 hours, could have influenced 
viscosity differences. As in, if the solution had been mixed longer it may have resulted in a less 
viscous solution. One additional factor that was discovered during the course of experimentation 
was temperature exposure. By default, the chitosan was on a heated stir plate during preparation. 
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This did not result in even heating. A sample vial that had been left in the incubator, in case it was 
needed to produce more samples, ended up being kept at 40C for several days. In contrast to the 
chitosan that was used during the sample production, this vial was quite liquid and not viscous at 
all.  
All the chitosan samples appeared as though they had beads of chitosan down their length, 
and that results in the wavy uneven quality that can be seen in the sample images. The speed that 
the samples were removed from their solution dips results in different physical properties for the 
coatings. If the samples are removed quickly, thicker coatings are produced. Removing the 
samples from their polymer slowly allows the polymer solution to slide down the sample and back 
into the mixture. Thus, removing the samples faster allows less to drip and creates a thicker 
coating. The samples will likely have been removed at varying speeds due to human variability. 
Varying the speed during a single removal could result in an uneven coating. Additionally, 
bumping the sample into the sides of the vial, or jolting the sample as it is moved can alter the 
surface consistency. These variabilities could have been removed using an automated process. 
7.1.2 Manufacturing Concerns 
 While the observable physical properties of the coatings themselves were closely analyzed 
and monitored during the testing, other aspects for manufacturing the coatings were also 
considered. Most notably, the safety of producing the polymer solution. Out of the three polymers 
that were tested, chitosan, PCL, and PLLA, the chosen polymer, chitosan, posed the least danger 
in its components for production. While PLLA required chloroform and PCL required acetone, 
both of which evaporate easily and produce toxic fumes, chitosan required only 5% acetic acid for 
its solvent, which is essentially vinegar. Aside from its weak solvent, chitosan required other fluids 
to fix it to the nitinol samples, ethanol and ammonia. Ethanol is the primary alcohol found in 
alcoholic beverages, and ammonia is a commonly used household cleaner. These chemicals are all 
safe enough to be readily purchasable for regular use at any department store.  
7.1.3 Mechanical 
 Due to scale limitations with the available mechanical testing system (the Instron 5544’s 
20N load cell), theoretical 3-point bending calculations were utilized. As such, the results of these 
calculations presented approximations of the applied force changes on the uncoated and coated 
wire samples. This was done by utilizing modulus-weighted area moments of inertia to examine 
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the contributions of both the wire and the different coatings. When comparing the bending 
moments of the uncoated and coated wires, it was apparent that the largest factor the resulted in a 
difference in the moments was the radius of the examined coating, since the moduli of all coatings 
were significantly smaller, ranging from 50 times smaller to nearly 10,000 times smaller than that 
of nitinol. As such, in the case of chitosan and PCL, the contribution of the elastic modulus was 
minimal, while the PLLA coated wire’s bending moment ratio to the uncoated wire was reduced 
by an additional 5% when compared to the ratio of the radii of this coated wire and its uncoated 
counterpart. This implies that the coating’s mechanical properties do not impact the bending 
moment of the wire as strongly as the increased radius. As such, the optimal thickness of the 
coating should be considered to prevent the mechanical integrity of the nitinol stent wires from 
lowering, which may lead to premature stent failure. 
7.1.4 Cytotoxicity 
Whether or not each of the materials tested were cytotoxic was a pass/fail test for if they 
could possibly be used as a long term implanted device. While this test was critically important all 
of the materials that were tested passed so it did not affect the overall coating material selection 
process. 
7.1.5 Cell Adhesion 
Cell and tissue adhesion is critical to the reduction of stent migration. By adhering the stent 
to the walls of the trachea it will be unable to move around and cause irritation and inflammation. 
The adhesion testing results used did not have clear results due to not being able to definitively tell 
whether cells had actually adhered to the wire samples or just accumulated around them. which 
resulted in literature being referred to instead of experimental data. It was clear from the literature 
that chitosan was the only polymer tested that had mucoadhesive properties [29].  
7.1.6 Cost Effective 
 While cost may have been the last aspect of the chitosan coating that was evaluated, it is 
no less important. Originally, it was decided that the cost of the coating needed to be less than 
$400 to keep the coated stent affordable. That goal was fulfilled due to the low cost of the chitosan 
dip coating. The cost to create on milliliter (mL) of the chitosan solution amounts to approximately 
$0.03, or $30/L. To put this in perspective, the samples produced in these tests were two-inch-long 
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samples of nitinol wire. Using a liter of the chitosan polymer solution, almost 550,000 coated 
samples could be created, under the assumption that they all produced an even coating of identical 
thicknesses.  
7.1.7 Summary 
 Overall, chitosan generally performed better than the competing polymers, PCL and PLLA, 
against the design objectives. While the average coatings of chitosan on the wire samples were 
uneven in thickness, they were at least consistently present. On PCL, it was uncertain if there was 
a successful coating every time. The chitosan coatings were also not thick enough to have much 
of an effect on how much force is needed to produce a stress in the wires. PLLA, on the other 
hand, produced coatings that were thick enough to decrease the required force by 30%.  
 All the polymers tested passed the cytotoxicity testing. The uncoated wire left 
approximately the same number of cells alive as the number of cells exposed, and the polymer 
coated samples performed the same. The only way for one of the polymers to perform better would 
have been for it to increase the overall cell growth.  
 The adhesion testing was never successfully completed. There were always some issues, 
ranging from staining issues to imaging issues to cell issues. Looking directly at chitosan, it 
potentially caused some of those errors. Chitosan is a biological polymer, so it can apparently take 
up some of the nucleic acid dyes used on cells. Moreover, even when there was careful preparation 
to ensure that no nucleic dye made it to the chitosan, chitosan would prove to have some innate 
autofluorescence. Taking this new information, it is possible that the original fluorescence of the 
chitosan was not due to the absorption of dye, but the inherent physical properties of the chitosan. 
This would cause issues until there was no longer any time to test. Going back to the research 
materials, chitosan was decided to have better adhesion based upon it’s mucoadhesive properties 
[30].  
 Finally, chitosan came out on top of the cost analysis. When cost was calculated on a 
volume of solution basis, chitosan’s cost was found to be $0.03/mL. PCL was found to be an order 
of magnitude above that value at $0.43/mL, and PLLA was an additional order of magnitude 
greater at $3.33/mL.  
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7.2 Limitations 
 The primary limitation of the chitosan coatings is attributed to the inconsistency of the 
coating. Through all the coating samples, the chitosan never produced an even coating. When it 
was removed from the polymer solution, the chitosan would always bead along the wire. 
Theoretically, chitosan should have produced nice coatings due to its viscous nature when in a 
solution with acetic acid. However, this was never evidenced.  
 Relating back to the literature, chitosan’s irregularity can be noted once more. Its overall 
degradation is neither bulk nor surface, but somewhere in between. This can make it very difficult 
to predict the degradation period, and also makes chitosan’s degradation period irregular. While 
this point of chitosan’s nature was not directly studied in these experiments, it would a have been 
one of the major aspects that would have needed to be studied once the polymer was chosen as the 
primary coating. It wouldn’t do any good for the coating to spontaneously break down shortly after 
the stent it is on is implanted. That would negate the whole purpose of the coating. 
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8.0 Conclusions and Recommendations 
8.1 Conclusions 
 The primary goal of this project was to design a product or process to improve existing 
stents and to promote the quality and longevity of canine tracheal collapse treatment. The 
objectives for the development of said product that were chosen to meet this goal were to reduce 
stent migration, maintain the trachea opening, be compatible with current manufacturing methods, 
and be low cost. Once it was decided that the product created in this project would be a coating for 
existing stents, the testing methodology was created. This methodology was a series of tests meant 
to validate that objectives were met and validate that the final design met the overall goal of the 
project. 
 The methodology followed in this project was to test the overall consistency of the tested 
coatings, analyze the manufacturing concerns of the coatings, test and identify the effects of the 
coatings on the mechanical properties of the nitinol wire, test the cytotoxicity of the coatings, test 
the overall ability of cells to adhere to the coating, and analyze the price of the coatings. The three 
polymers that were tested were chitosan, PCL, and PLLA.  
 When analyzed for coating consistency, it was determined that chitosan consistently 
produced quality coatings while PCL and PLLA did not. This was because, while chitosan 
produced uneven coatings, the thin or thick coatings of PCL and PLLA, respectively, were 
detrimental. The miniscule PCL coatings and the thick PLLA coatings presented manufacturing 
concerns. Chitosan, however, did not present any of these concerns. Looking at the mechanical 
integrity of the samples, the only polymer that increased the stress applied to the wire was PLLA. 
It weakened the overall samples by approximately 30%. Chitosan and PCL both decreased the 
strength of the samples as well, but at most by 10%, which was decided to be negligible. The 
cytotoxicity testing found that all polymer coatings were comparable to the current bare nitinol in 
that they did not increase or decrease the viability of the tested cells. As the adhesion testing failed 
in general, looking at the literature was required to conclude this test. Based on what was found, it 
was decided that chitosan passed while PCL and PLLA failed. This was because chitosan has been 
shown to exhibit mucoadhesive properties, while both PCL and PLLA showed records of allowing 
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more freedom of movement [30]. Finally, looking at cost, chitosan had the best cost at $0.03 per 
mL, PLLA has the worst cost at $3.33 per mL, and PCL was neutral with a cost of $0.43 per mL. 
 Going over the results of the testing, chitosan was chosen as the final candidate for the 
polymer stent coating. While chitosan did perform neutrally in several of the tests, it also was the 
only tested polymer to perform positively in any of the tests. Both PCL and PLLA only showed 
neutral or negative results, with PLLA having more negative results than PCL. In summary, this 
project finds that chitosan fulfilled the project objectives better than the bare wire, PCL, and PLLA. 
This coating would increase the overall longevity of the stents by decreasing the micromotion of 
the stent in the trachea, which should decrease the long term swelling and stenosis that tends to 
develop around canine tracheal stents and decrease their lifespans.  
8.2 Future Work 
 After reaching the limit of the time that the team had available to work on this project, there 
were still several aspects of the project that were left incomplete. Additionally, new aspects were 
determined to be important for further developing this coating. Most notable and obvious of these 
was the need to continue with adhesion testing. There was not a successful conclusion reached 
from the adhesion tests that were performed, as the tests had all failed in some capacity. The major 
reason that these tests failed is likely due to chitosan has the property of autofluorescence. As such, 
any future adhesion testing would need to account for this. From the images that were taken, it 
appeared that the chitosan fluoresced blue. So, to fix this, it might be beneficial to utilize red and 
green dyes on the cells rather than the green and blue dyes. Other possible methods to test the 
adhesion that could be used are using a nitinol sheet instead of a wire, giving the cells a larger 
surface area to attach to, or using a bundle of wires.  
 Throughout the testing for this project, a solution of 2% w/v chitosan and 5% acetic acid 
was used. However, it was not measured properly at one point during the process, resulting in the 
concentration being closer to 5% w/v chitosan. The resulting solution was significantly more 
viscous, to the point of nearly being solid. As such, a further point of research would be to vary 
the concentrations of chitosan and acetic acid in the samples to examine what effects that would 
have on the final coatings. Due to monetary constraints, it was decided that this testing was beyond 
the project scope.  
 80 
 
 For the imaging of the samples, a microscope at 20x power was used. This only produced 
images of a resolution that is less than 1 microns. Originally, it was intended that Scanning Electron 
Microscopy (SEM) would be used on the chosen final products to characterize them in even more 
detail, as it has a resolution of 10 nanometers and would have shown even the thinnest of the 
coatings we produced. However, due to time constraints, this never occurred. Further testing 
should involve the use of SEM to verify coating thickness with higher accuracy than the utilized 
imaging methods. Additionally, SEM can validate coating distribution and topography. 
 A point that it is necessary to note is that only single wires were coated during these tests. 
While the wires were being used as stand-ins for actual stents, they lacked some of the mechanical 
properties that result from the stent being made from a wire mesh. To this end, it would be 
important to perform the tests again on a whole stent that had been coated. The mechanical 3-point 
bending tests could be validated on the whole stent using physical 3-point bending. As the actual 
tests were inconclusive and theoretical calculation were used instead, it is vital that the actual 
mechanical properties of the coated stent be tested. The theoretical calculation only represents the 
mechanical properties of a single wire, and the stent could potentially react differently when 
coated.  
 Upon successful refinement and validation of the coating method, it would be important to 
perform in vivo testing on the coated stents. All the experiments performed in this project were 
designed to be in vitro representations of in vivo conditions, but there were limitations in some 
replications of these properties. For example, the adhesion testing would benefit from being 
performed in a mucosal environment, so the mucoadhesive properties of the chitosan could have 
been verified. However, the reproduction or collection of mucosal tissue was beyond the 
capabilities of the team. In vivo testing would provide the correct environment to confirm the 
mucoadhesive properties of chitosan, as well as the stent’s behavior when it is deployed in a 
functional, living system.   
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Appendix A: Experimental Methods 
Coating Methods: 
Chitosan Dip Coating Method 
Dissolve the Chitosan in 5% Acetic Acid [49] 
 2% w/v 
40C with stirring for 1.5 hr 
Dip the nitinol wire into the Chitosan solution for 2 min 
Move the dipped wire to the fixing solution for 5 min 
 The fixing solution should be 2 parts ammonia to 1 part ethanol [56] 
Allow dipped wire to dry for 24 hr, at 40C 
Wash the dipped wire with the fixing solution 
 Just to make sure no acid remains 
Allow the dipped wire to dry at 40C 
PLLA Dip Coating Method 
Dissolve the PLLA in chloroform [47] 
 5-10% w/v(5% w/v for experiment) 
 Stirring at room temp 
Dip the nitinol wire into the solution for 2 min 
Remove wire and allow to dry for 24 hr @ 40C 
Rinse with DI water 
Allow to dry at 40C 
PCL Dip Coating Method 
Dissove the PCL in acetone [48] 
1-5%  w/v(5% w/v for experiment) 
 Stirring at room temp for up to 6 hours 
Dip the nitinol wire in the solution for 2 min 
Remove wire and allow to dry for 24hr @ 40C 
Rinse with DI water 
Allow to dry at 40C 
 
PDMS Mold Protocol 
 Weigh 100 grams of silicon polymer base and 10 grams of silicon polymer curing agent per batch 
 Mix both together thoroughly and poured into PETG mold with v-shaped notches, until about filled 1mm 
from top of mold ( this allows for the PDMS to become a negative of this, allowing the agar wells to obtain 
v-shaped notches) [55] 
o Printed on a Wanhao i3 3D printer with micro-swiss all metal hotend 
o Printed using MakerGeeks 1.75mm HD Blue Glass PETG filament 
 Degas in degassing chamber for 30 minutes, depressurizing the chamber as bubbles reach the surface of the 
PDMS 
 PDMS cured in mold in oven at 60°C for 1 hour 
 PDMS gel negatives removed from the mold using forceps and a spatula 
 Placed in autoclave pouch with necessary instruments place in 6-well plates and to flip solidified agar 
 Autoclaved on dry cycle 
Agar Well Protocol 
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 Autoclaved 500 mL of 2% agar dissolved in deionized water solution on liquid cycle 
 PDMS negatives placed in 6-well plates with ridges upward 
 Warm PDMS poured into 6-well plate using pipette controller 
o Approximately 8 mL per well 
 Taped plates closed, allowed to cool refrigerator 
 Following cooling, solidified agar wells are flipped over in plate, PDMS is removed and disposed of, agar 
wells plated notch up 
 Taped plates closed, stored inverted in refrigerator until time of use 
MTT Assay 
Materials 
 Reagent  
 Tissue culture 96 well plate 
 100 µL pipet 
Protocol 
1. Culture cells in a 96 well plate and allow cells to grow for 48 hours. 
2. Thaw reagent for about 90 min at room temp 
a. Ensure the entire vial is thawed before use 
3. Pipet 20 μL of reagent into each desired well of a 96 well plate. 
a. Each well should already have 100 μL of cell/media mixture 
4. Incubate the plate for 1 to 4 hours at 37 degrees and 5% CO2 
a. 25 μL of 10% SDS can be used to stop the reaction if the plates are then placed in a dark 
room temp humidified chamber for up to 18 hours 
5. Record absorbance at 490nm 
Plate Set Up 
Standard 
Curve 
Un-coated 
nitinol 
Chitosan 
coated nitinol 
PLLA PCL Control 
(media) 
50k cells 40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
0 cells 
40k cells 40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
0 cells 
30k cells 40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
40k cells (7-
day old media) 
0 cells 
20k cells 40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
0 cells 
10k cells 40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
0 cells 
0 cells 40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
40k cells (14-
day old media) 
0 cells 
 
Cell Adhesion Seeding 
 Utilizes fibrin microthreads in procedure, substitute these for wires (coated and uncoated) 
 Length used: 2 in 
 Diameter: 0.006 in 
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 Sterilization:  
 Wires washed with 15 minutes PBS  
 45 minutes 70% ethanol 
 3 rinses for 15 each in PBS 
 V-shaped channel fabrication + cell seeding 
 2g agar added to 100 ml of DI water (2% solution made) then autoclaved 
 Solution poured into pyramid shaped mold and gels for 45 minutes 
 Template removed, v-shaped agarose chamber transferred to cell culture wells using 
spatula 
 Culture wells filled with DMEM around v-shaped chamber prior to cell seeding 
 Sterilized wires anchored to bottom of chamber using triangle slabs made of PDMS 
 Cells seeded onto wires and incubated for 4 hours (might vary dependent on cell type) 
 Nuclei visualization: 
 Rinse samples w/ PBS to remove unattached cells 
 Stained for 5 minutes with Hoechst nuclear dye, mounted on slide, and viewed under 
inverted fluorescent microscope 
 Included unseeded wires as negative control 
 Cell quantification: 
 CyQuant NF cell proliferation kit 
 Seeded threads trypsinized to isolate cells from thread, followed by centrifugation 
 50 microLiter solution of 1X CyQuant dye added to each cell pellet and transferred to 96-
well plate 
 Plates incubated for 45 minutes 
 Plates read using fluorescence microplate reader to measure fluorescence units in sample 
wells 
 Unseeded threads used as negative control 
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